WO2017132694A1 - Dispositifs de perfusion acoustique - Google Patents

Dispositifs de perfusion acoustique Download PDF

Info

Publication number
WO2017132694A1
WO2017132694A1 PCT/US2017/015689 US2017015689W WO2017132694A1 WO 2017132694 A1 WO2017132694 A1 WO 2017132694A1 US 2017015689 W US2017015689 W US 2017015689W WO 2017132694 A1 WO2017132694 A1 WO 2017132694A1
Authority
WO
WIPO (PCT)
Prior art keywords
acoustic
standing wave
cells
fluid
ultrasonic transducer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2017/015689
Other languages
English (en)
Inventor
Bart Lipkens
Jr. Walter M. Presz
Louis Masi
Benjamin Ross-Johnsrud
Erik Miller
Thomas J. Kennedy Iii
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Flodesign Sonics Inc
Original Assignee
Flodesign Sonics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/139,187 external-priority patent/US9752113B2/en
Application filed by Flodesign Sonics Inc filed Critical Flodesign Sonics Inc
Priority to GB1812196.2A priority Critical patent/GB2562937B/en
Priority to CA3013052A priority patent/CA3013052A1/fr
Publication of WO2017132694A1 publication Critical patent/WO2017132694A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M47/00—Means for after-treatment of the produced biomass or of the fermentation or metabolic products, e.g. storage of biomass
    • C12M47/02—Separating microorganisms from the culture medium; Concentration of biomass
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D17/00—Separation of liquids, not provided for elsewhere, e.g. by thermal diffusion
    • B01D17/02—Separation of non-miscible liquids
    • B01D17/04—Breaking emulsions
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D17/00—Separation of liquids, not provided for elsewhere, e.g. by thermal diffusion
    • B01D17/06—Separation of liquids from each other by electricity
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D21/00—Separation of suspended solid particles from liquids by sedimentation
    • B01D21/28—Mechanical auxiliary equipment for acceleration of sedimentation, e.g. by vibrators or the like
    • B01D21/283—Settling tanks provided with vibrators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M29/00—Means for introduction, extraction or recirculation of materials, e.g. pumps
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M29/00—Means for introduction, extraction or recirculation of materials, e.g. pumps
    • C12M29/10—Perfusion
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M33/00—Means for introduction, transport, positioning, extraction, harvesting, peeling or sampling of biological material in or from the apparatus
    • C12M33/08—Means for introduction, transport, positioning, extraction, harvesting, peeling or sampling of biological material in or from the apparatus by vibration
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M35/00—Means for application of stress for stimulating the growth of microorganisms or the generation of fermentation or metabolic products; Means for electroporation or cell fusion
    • C12M35/04—Mechanical means, e.g. sonic waves, stretching forces, pressure or shear stimuli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M47/00—Means for after-treatment of the produced biomass or of the fermentation or metabolic products, e.g. storage of biomass
    • C12M47/10—Separation or concentration of fermentation products

Definitions

  • a perfusion bioreactor processes a continuous supply of fresh media that is fed into the bioreactor while growth-inhibiting byproducts are constantly removed. The nonproductive downtime can be reduced or eliminated with a perfusion bioreactor process.
  • the cell densities achieved in perfusion culture (30-100 million cells/mL) are typically higher than for fed-batch modes (5-25 million cells/mL). These improvements have led to lower contamination in the harvest and better yields without significant increase in cost.
  • a perfusion bioreactor may use a cell retention device to prevent escape of the culture when byproducts are being removed. These cell retention systems may add a level of complexity to the perfusion process, where further management, control, and/or maintenance operations may be implemented. Operational issues such as malfunction or failure of the cell retention equipment has previously been a problem with perfusion bioreactors, which has limited their attractiveness in the past.
  • the present disclosure relates, in various embodiments, to acoustic devices which are used for perfusion biomanufacturing. More particularly, the devices are coupled to an associated bioreactor. Within the bioreactor, biomolecules, such as recombinant proteins or monoclonal antibodies, and other materials are produced. Materials may include viruses, virus-like particles, exosomes, oncozomes, materials from cell free protein synthesis, cell vesicles, proteins, monoclonal antibodies, recombinant proteins and other materials.
  • the acoustic device is used for separating desirable products from the bioreactor contents on a continuous basis, and the cells or other materials are continuously returned to the bioreactor for further culturing.
  • a fluid mixture containing the cells and the desired products are passed or flowed through the acoustic device and separated therein by multi-dimensional standing wave(s).
  • the fluid mixture generally also contains other materials, such as cell debris and fines.
  • the fluid mixture can be continuously flowed into the device, with desired products being continuously removed.
  • the acoustic perfusion device returns healthy viable cells to the bioreactor while desired products are harvested and flowed downstream for further processing, e.g., additional filtering, chromatography, etc.
  • the cell culture media in the bioreactor is clarified as cell fragments are also allowed to pass into the harvest stream and thereby out of the fluid mixture being recycled to the bioreactor. This arrangement results in lower overall cell culture media usage, corresponding to a predicted cost savings of up to $20,000 per day for large bioreactors.
  • acoustic perfusion devices comprising: an acoustic chamber; an inlet port, an inlet flow path leading from the inlet port to the acoustic chamber; an outlet port for recirculating fluid flowing through the device back to its source (e.g.
  • a bioreactor a bioreactor
  • an outlet flow path leading from the acoustic chamber to the outlet port at least one collection or harvest port for collecting a product stream of fluid exiting the acoustic chamber
  • at least one ultrasonic transducer in the acoustic chamber below the at least one harvest port the at least one ultrasonic transducer including a piezoelectric material driven by a drive signal to create an acoustic standing wave across a collection or harvest flow path leading from the acoustic chamber to the at least one collection or harvest port.
  • the acoustic standing wave may be planar or multi-dimensional, or a combination of such waves may be present within the acoustic chamber (generally from multiple transducers).
  • the acoustic standing wave can be thought of as a "force field" that holds back whole cells but permits smaller materials such as the desired biomolecules (e.g. recombinant proteins and/or monoclonal antibodies) and cell fragments, to pass through and be removed from the fluid that is returned to the bioreactor.
  • desired biomolecules e.g. recombinant proteins and/or monoclonal antibodies
  • cell fragments e.g. cell fragments
  • the outlet port is generally below the inlet port, and is generally located at a bottom end of the device.
  • the device may have one or more collection or harvest ports at the top of the device.
  • the device may have a total of two harvest ports spaced apart from each other on the top end of the device.
  • the inlet port is at a first end of the device at a first height
  • the at least one ultrasonic transducer is at a second height above the first height
  • a bottom wall extends from the inlet port to the outlet port.
  • the outlet port may be located at a second end of the device opposite the first end.
  • the bottom wall may be concave, relative to a line between the inlet port and the outlet port.
  • the device may include an upper wall above the inlet flow path.
  • the inlet port, the outlet port, and the at least one harvest port are sometimes all located on a front wall of the device.
  • the front wall itself may be planar (i.e. flat).
  • the device can further comprise a reflector located in the acoustic chamber opposite the at least one ultrasonic transducer.
  • the device can have a total of two ultrasonic transducers located on opposite sides of the harvest flow path at the same height and facing each other, or additional ultrasonic transducers can be located on multiple sides of the collection/harvest flow path.
  • a reflector may be located between the two ultrasonic transducers.
  • There may also be a plurality of transducer / reflector pairs located as appropriate to form planar, multi-dimensional, or combinations of such acoustic standing wave(s).
  • the acoustic standing wave results in an acoustic radiation force having an axial force component and a lateral force component that are of the same order of magnitude.
  • the inlet flow path leads from the inlet port downwards towards a bottom end of the device and past the outlet port, and then upwards to the acoustic chamber.
  • the inlet port and the at least one harvest port are both located on a top wall of the device, and the outlet port is located on a front wall of the device.
  • the at least one ultrasonic transducer may be mounted in a rear wall or a front wall of the device.
  • the bottom wall of this acoustic chamber can be a sloped planar surface.
  • the reflector may be made of a transparent material.
  • the inlet flow path may be shaped to generate a tangential flow path below an acoustic field generated by the acoustic standing wave.
  • the inlet flow path enters the acoustic chamber on a first side of the device, and the outlet port is located (i) on the first side of the device or (ii) on a second opposite side.
  • the inlet port can be located on a front side of the device, and the at least one harvest port can be located on a top wall of the device.
  • the at least one transducer can be located on a front side or a rear side of the device. In more particular embodiments, there can be two transducers, one on the front side and one of the rear side. In yet other particular embodiments, there is an ultrasonic transducer on the front or rear side, and a reflector located on the respective rear or front side opposite the transducer.
  • the perfusion device further comprises a recirculation flow path between the inlet port and the outlet port that does not enter the acoustic chamber, and the recirculation flow path is located below the acoustic chamber.
  • the inlet flow path travels through a different passage than the outlet flow path.
  • the inlet flow path and the outlet flow path travel through a common passage.
  • the device may be attached to a mounting piece having holes for attachment.
  • the fluid mixture is flowed through an acoustic perfusion device of the structure described above, having at least one ultrasonic transducer.
  • the at least one ultrasonic transducer is driven to create the acoustic standing wave.
  • a fluid enriched in cells can be collected from the outlet port and a clarified fluid, depleted in cells, can be collected from the at least one harvest port.
  • the flow rate through the collection / harvest flow path is at least one order of magnitude smaller than a flow rate through the inlet flow path.
  • a flow rate of the fluid mixture entering the device through the inlet port is about 1 liter per minute and a flow rate of the fluid depleted in cells exiting the device through the at least one collection / harvest port is about 10 milliliters per minute.
  • the ratio of the flow rate entering through the inlet port to the flow rate exiting through the at least one collection / harvest port is such that the acoustic standing wave is not overcome by the main body of cells, or in other words so that a large volume of cells do not begin exiting the device through the collection / harvest port(s).
  • the methods may further comprise pulling the fluid mixture through the device using a first pump attached to the at least one harvest port of the device and a second pump attached to the outlet port of the device.
  • flow devices adapted to (i) receive a flowing mixture containing a primary fluid and cells; and (ii) to use a first acoustic standing wave to continuously draw off a harvest fluid stream depleted in cells from the flowing mixture, thereby changing the cell concentration of the flowing mixture.
  • a pressure rise may be generated on the upstream interface region of the acoustic standing wave, along with an acoustic radiation force acting on the incoming suspended particles.
  • This "interface effect” which may also be termed “edge effect” acts as a barrier and is typically located at the upstream bounding surface of the volume of fluid that is ensonified by the transducer (i.e. the flow mixture crosses the interface region to enter the ensonified volume of fluid).
  • the frequency of the acoustic standing wave may be modified such that different contrast factor materials may be held back or allowed through the acoustic standing wave, or such that particles of one given size range are retained and particles of a second given range are allowed to flow through the standing wave.
  • the device may further comprise a secondary flow chamber in which the harvest fluid stream depleted in cells passes through a second acoustic standing wave having a frequency different from, or equal to the first acoustic standing wave.
  • the second acoustic standing wave may have a higher or lower frequency than the first acoustic standing wave.
  • the ratio of the frequency of the two standing waves is, in some embodiments, at least 2:1 (i.e. one of the frequencies is at least twice the other frequency, e.g. 3 MHz and 6 MHz).
  • flow devices that comprise: at least one inlet for receiving a flowing mixture of a primary fluid and cells, an ultrasonic transducer that produces a first ultrasonic acoustic standing wave and uses a pressure rise and an acoustic radiation force generated on an upstream interface region of the first ultrasonic acoustic standing wave to separate the flowing mixture into a primary high cell concentration fluid stream and a secondary harvest fluid stream; an outlet port for the primary high cell concentration fluid stream; and at least one collection port for the secondary harvest fluid stream.
  • a bleed port can also be present for extracting a concentrated fluid/cell mixture.
  • the fluid mixture may comprise particles such as mammalian cells, bacteria, cell debris, fines, proteins, exosomes, vesicles, viruses, and insect cells.
  • the device may further comprise a secondary flow chamber in which the secondary harvest fluid stream passes through a second acoustic standing wave having a frequency different from, or equal to, the first ultrasonic acoustic standing wave.
  • the methods comprise flowing a mixture containing a host fluid, the beads, and the cells through an acoustophoretic device; sending a voltage signal to drive an ultrasonic transducer to create the multi-dimensional acoustic standing wave, wherein a recirculating fluid stream having a tangential flow path is located substantially tangential to the multi-dimensional acoustic standing wave and separated therefrom by an interface region; and wherein at least a portion of the cells (e.g., at least 95% of the cells, including up to about 99% of the cells) pass through the multi-dimensional acoustic standing wave, and the beads are held back from the multidimensional acoustic standing wave in the recirculating fluid stream at the interface region.
  • the cells e.g., at least 95% of the cells, including up to about
  • the acoustophoretic device may be constructed as described herein, namely comprising a flow chamber having at least one inlet and at least one outlet; at least one ultrasonic transducer located in the flow chamber, the at least one ultrasonic transducer including a piezoelectric material driven by a voltage signal to create a multidimensional acoustic standing wave in the flow chamber; and a reflector located in the flow chamber opposite from the at least one ultrasonic transducer.
  • the beads are non-functionalized.
  • Other embodiments include functionalizing the beads such that the beads attach to the cells.
  • the beads can be functionalized with various materials, such as antigens, on the surface that will allow for affinity binding of materials (e.g., viruses, virus-like particles, exosomes, oncozomes, materials from cell free will protein synthesis, proteins, monoclonal antibodies, recombinant proteins) to the beads.
  • the functionalized beads may, in some embodiments, have a positive contrast factor.
  • the functionalized beads having a positive contrast factor may be selected from the group consisting of polystyrene beads and glass beads. In other embodiments, have a negative contrast factor.
  • the functionalized beads having a negative contrast factor may be selected from the group consisting of microbubbles and micro-glass spheres.
  • the beads may, in certain embodiments, be polymeric, glass, hollow, or gas-filled.
  • the beads can be spherical, toroidal, cylindrical, or conical.
  • the mixture can include microvesicles (e.g., exosomes, oncosomes, viruses, proteins, recombinant proteins, and monoclonal antibodies).
  • a pressure rise and an acoustic radiation force on cells can be generated at the interface region to clarify the host fluid as it passes through the multi-dimensional acoustic standing wave.
  • the method further comprises collecting the cells after passing through the multi-dimensional acoustic standing wave for a first time and recirculating the collected cells are back through the device for separation by the multi-dimensional acoustic standing wave for a second time.
  • the method can further comprise collecting the cells after passing through the multidimensional acoustic standing wave for the second time.
  • acoustophoretic devices including a flow chamber having at least one inlet port and at least one outlet; at least one ultrasonic transducer coupled to the flow chamber and at least one reflector coupled to the flow chamber opposite the at least one ultrasonic transducer, wherein the at least one ultrasonic transducer includes a piezoelectric material driven by a voltage signal to create a multidimensional acoustic standing wave in the device; and a coolant inlet adapted to permit the ingress of an associated cooling fluid into the device for cooling the at least one ultrasonic transducer.
  • the at least one inlet port includes a first inlet port on a front wall of the device, a second inlet port on a rear wall of the device opposite the front wall thereof, and the at least one outlet includes a permeate outlet on the first sidewall of the device, a wastewater outlet on the first sidewall of the device, and a drain outlet on a first sidewall of the device.
  • the cooling fluid can be the same or different from the primary fluid that flows through the flow chamber carrying particles (e.g., cells and beads).
  • the cooling fluid can be water, air, alcohol, ethanol, ammonia, or some combination thereof.
  • the cooling fluid can, in certain embodiments, be a liquid, gas, or gel.
  • the cooling fluid can be an electrically non-conductive fluid to prevent electric short-circuits.
  • Figure 1 illustrates a single standing acoustic wave generated by an ultrasonic transducer and a reflector.
  • Figure 2 is an illustration comparing a fed-batch bioreactor system with a perfusion bioreactor system.
  • Figure 3 is a cross-sectional view that shows the various components of a stirred-tank bioreactor.
  • Figure 4 is a perspective view of one exemplary embodiment of an acoustic perfusion device of the present disclosure, having two collection or harvest ports and a single ultrasonic transducer.
  • Figure 5 shows a second exemplary embodiment of an acoustic perfusion device of the present disclosure, with a single reflector located between two ultrasonic transducers.
  • Figure 6 is a schematic view illustrating a perfusion bioreactor coupled with an acoustic perfusion device of the present disclosure, and a recycle path.
  • Figure 7 is a front cross-sectional view of a third exemplary embodiment of an acoustic perfusion device of the present disclosure.
  • Figure 8 is an exterior perspective view of the acoustic perfusion device of Figure 7.
  • Figure 9 is a front cross-sectional view of a fourth exemplary embodiment of an acoustic perfusion device of the present disclosure.
  • Figure 10 is a perspective view of the acoustic perfusion device of Figure 9.
  • Figure 11 is a cross-sectional diagram of a conventional ultrasonic transducer.
  • Figure 12 is a cross-sectional diagram of an ultrasonic transducer of the present disclosure. An air gap is present within the transducer, and no backing layer or wear plate are present.
  • Figure 13 is a cross-sectional diagram of an ultrasonic transducer of the present disclosure. An air gap is present within the transducer, and a backing layer and wear plate are present.
  • Figure 14 is a graph of electrical impedance amplitude versus frequency for a square transducer driven at different frequencies.
  • Figure 15 illustrates the trapping line configurations for seven of the resonance frequencies (minima of electrical impedance amplitudes) of Figure 14 from the direction orthogonal to fluid flow.
  • Figure 16 is a computer simulation of the acoustic pressure amplitude (right- hand scale in Pa) and transducer out of plane displacement (left-hand scale in meters).
  • the text at the top of the left-hand scale reads "x10 "7 ".
  • the text at the top of the left- hand scale by the upward-pointing triangle reads "1.473x10 "6 ".
  • the text at the bottom of the left-hand scale by the downward-pointing triangle reads "1.4612x10 "10 ".
  • the text at the top of the right-hand scale reads "x10 6 ".
  • the text at the top of the right-hand scale by the upward-pointing triangle reads "1 .1 129x10 6 ".
  • the text at the bottom of the right- hand scale by the downward-pointing triangle reads "7.357".
  • the triangles show the maximum and minimum values depicted in this figure for the given scale.
  • the horizontal axis is the location within the chamber along the X-axis, in inches
  • the vertical axis is the location within the chamber along the Y-axis, in inches.
  • Figure 17 shows the In-Plane and Out-of-Plane displacement of a crystal where composite waves are present.
  • Figure 18 is a view of a first acoustic perfusion device of the present disclosure fluidly connected to an associated bioreactor, showing a plurality of hoses fluidly connecting the various ports of the device to the associated bioreactor and an outflow pump fluidly connecting the outlet port of the device to the associated bioreactor.
  • Figure 19 is a view of another acoustic perfusion device of Figure 5, showing a reflector in the acoustic chamber between first and second transducers. A fluid mixture is also present in the device and arrows are shown indicating the direction of flow in addition to waves indicating the acoustic field between the reflector and first and second transducers.
  • Figure 20 is a graph showing the efficiency of removing cells from a fluid mixture for one experiment at two different perfusate/feed rates.
  • Figure 21 is a graph showing the harvest flow (also referred to as the perfusate) turbidity reduction for an experiment
  • Figure 22 is a graph showing the cell viability for varied flow rates for the experiment conducted for the graphs of Figures 20-21.
  • Figure 23 is a graph showing the total cell density and cell retention for varied flow rates and flow methods for another experiment.
  • Figure 24 is a graph showing the cell viability for varied flow rates for the experiment conducted for the graphs of Figure 23.
  • Figure 25 is a graph showing the total cell density and cell retention for varied numbers of ultrasonic transducers for another experiment.
  • Figure 26 is a graph showing the cell viability for varied numbers of ultrasonic transducers for the experiment conducted for the graph of Figure 25.
  • Figure 27 is a picture of another acoustic perfusion device that was tested.
  • Figure 28 is a graph showing the effect of the perfused flow rate or the transducer voltage on the cell retention.
  • Figure 29A is a microscope image from a ViCell Cell Analyzer of the particles in the feed stream going into the device.
  • the feed stream is a bioreactor fluid containing CHO cells, protein, and cell fragments.
  • Figure 29B is a graph of the particle diameter distribution of the feed, showing a bimodal distribution.
  • the y-axis is the particle count from 0 to 200 in intervals of 10.
  • the x-axis is the particle diameter in microns from 6 to 50 in intervals of 2.
  • the total number of particles is 5539, the mean particle size is 16.78 microns, standard deviation of 6.76 microns, and mode particle size of 10.56 microns.
  • Figure 30A is a microscope image of the perfusate (or clarified harvest flow) exiting the device.
  • Figure 30B is a graph of the particle diameter distribution of the perfusate, showing a unimodal distribution at much lower sizes.
  • the y- axis is the particle count from 0 to 300 in intervals of 20.
  • the x-axis is the particle diameter in microns from 6 to 50 in intervals of 2.
  • the total number of particles is 2919, the mean particle size is 10.08 microns, standard deviation of 3.75 microns, and mode particle size of 8.99 microns.
  • Figure 31 is a CFD model showing the velocity distribution within the device of Figure 27.
  • the text at the top of the scale reads "x10 "2 ".
  • the text at the top of the scale by the upward-pointing triangle reads "0.678".
  • the text at the bottom of the scale by the downward-pointing triangle reads "0".
  • the triangles show the maximum and minimum values depicted in this figure for the given scale.
  • the scale runs from 0 to 5 m/s in intervals of 0.5, with black indicating 5 at the top of the scale, and white indicating zero at the bottom of the scale.
  • Figure 32 is a front view of the device of Figure 27, showing the flow paths, acoustic field, and acoustic interface effect.
  • Figure 33 is a composite photograph showing the acoustic perfusion device of Figure 27 in two operating modes. On the left, the device is in startup or cell settling mode. On the right, the device is in steady cell retention mode.
  • Figure 34 shows the geometry of a model simulation of the acoustic device used for cell retention.
  • the model contains two fluids, one a clarified fluid within the acoustic field, the other a high cell density fluid to the left of the acoustic field, a piezoelectric transducer, a steel reflector, and an aluminum housing.
  • the first fluid was water within the acoustic field and the second fluid was a 15% concentration of CHO cells in water solution outside (to the left) of the acoustic field.
  • the blue solid line in the model indicates the separation line between the two fluids.
  • Figures 35A, 35B, and 35C are graphs showing the displacement of the piezoelectric material, the aluminum housing, and the steel reflector (left-side scale); and the acoustic pressure in the two fluids (right-side scale) of the model simulation of Figure 34 at several frequencies of operation.
  • Figure 35A is at a frequency of 2.218 MHz.
  • Figure 35B is at a frequency of 2.2465 MHz.
  • Figure 35C is at a frequency of 2.3055 MHz.
  • the left-side scale is indicated with text at the top of the scale reading "x10 "6 " or "x10 "7 ", and is in units of inches.
  • the right-side scale is indicated with text at the top of the scale reading "x10 6 ", and is in units of Pascals.
  • the y-axis runs from -0.8 to 1.6 in intervals of 0.2.
  • the x-axis runs from -0.5 to 1 .5 in intervals of 0.5.
  • Figure 36 is a graph showing the average lateral force (N) and the average lateral force normalized by power (N/W) acting on suspended CHO cells at several frequencies of operation.
  • Figure 37 is a picture (top view) of an acoustic perfusion device of the present disclosure. Arrows indicate the flow into the inlet port; the flow out of the outlet port; the clarified fluid flow out the top of the device and the flow of concentrate out the bottom of the device.
  • Figure 38 is a picture (side view) of the acoustic perfusion device of Figure 37.
  • Figure 39 is a graph of cell retention vs. perfusate flowrate for the device of Figure 37.
  • Figure 40 is a prior art illustration showing direct flow filtration (DFF) and tangential flow filtration (TFF).
  • Figure 41 is a picture illustrating a first mode of operation during perfusion, in which cells are trapped, clustered, and separated from a harvest stream.
  • the device is operated vertically, with an arrow indicating the direction of gravity.
  • Figure 42 is a picture illustrating a second mode of operation during perfusion, in which cells are prevented from entering an acoustic standing wave field while smaller particles are permitted to pass through the field and into the harvest stream.
  • the device is operated vertically, with an arrow indicating the direction of gravity.
  • Figure 43 is a perspective view of a fifth exemplary embodiment of an acoustic perfusion device of the present disclosure.
  • This embodiment includes a direct recirculation flow path between the inlet port and the outlet port.
  • An inflow passageway and an outflow passageway join the recirculation flow path to the acoustic chamber, and create a tangential sweeping flow underneath the acoustic field.
  • Figure 44 is a front view picture of the device of Figure 43. The inflow passageway and the outflow passageway are clearly visible, along with the recirculation pipe.
  • Figure 45 is a diagrammatic side view of the device of Figure 43.
  • Figure 46A and Figure 46B are a diagrammatic front view of the device of Figure 43, showing one internal structure. The figures are duplicated due to the number of reference numerals.
  • Figure 46C and Figure 46D are a diagrammatic front view of the device of Figure 43, showing an alternative internal structure, where the inflow passageway and the outflow passageway have a different flow geometry.
  • the figures are duplicated due to the number of reference numerals.
  • Figure 47 is a perspective view of a sixth exemplary embodiment of an acoustic perfusion device of the present disclosure.
  • This embodiment includes a direct recirculation flow path between the inlet port and the outlet port.
  • a single passageway joins the recirculation flow path to the acoustic chamber, and acts as both the inflow passageway and the outflow passageway.
  • Figure 48 is a diagrammatic side view of the device of Figure 43.
  • Figure 49 is a diagrammatic front view of the device of Figure 43, showing the internal structure.
  • Figure 50 is a graph of cell retention versus time for the device of Figure 7.
  • the y-axis runs from 90% to 100% in intervals of 1 %.
  • the x-axis runs from 0 to 165 minutes in intervals of 15 minutes. Tests were performed on two different days.
  • Figure 51 is a graph of perfusate cell density (million cells/mL) versus time for the device of Figure 7.
  • the y-axis runs from 0.00 to 3.50 in intervals of 0.50.
  • the x-axis runs from 0 to 165 minutes in intervals of 15 minutes. Tests were performed on two different days.
  • Figure 52 is a CFD model showing the velocity distribution within the device of Figure 46A.
  • the text at the top of the scale reads "x10 "3 ".
  • the scale runs from -5 to 5 m/s in intervals of 1 .
  • Figure 53 is a CFD model showing the velocity distribution within the device of Figure 46C at 250 mL/min flowrate.
  • the text at the top of the scale reads "x10 "3 ".
  • the scale runs from -5 to 5 m/s in intervals of 1.
  • Figure 54 is a CFD model showing the velocity distribution within the device of Figure 46C at 1000 mL/min flowrate.
  • the text at the top of the scale reads "x10 "3 ".
  • the scale runs from -5 to 5 m/s in intervals of 1 .
  • Figure 55 is a CFD model showing the velocity distribution for another internal structure for the device of Figure 43.
  • the scale runs from -0.05 to 0.1 m/s in intervals of 0.05.
  • Figure 56 is a CFD model showing the velocity distribution for another internal structure for the device of Figure 43.
  • the scale runs from -0.1 to 0.15 m/s in intervals of 0.05.
  • Figure 57 is a graph of cell retention versus time for the device of Figure 46A.
  • the y-axis runs from 90% to 100% in intervals of 1 %.
  • the x-axis runs from 0 to 100 minutes in intervals of 10 minutes.
  • Figure 58 is a graph of perfusate cell density (million cells/mL) versus time for the device of Figure 46A.
  • the y-axis runs from 0.00 to 1 .20 in intervals of 0.20.
  • the x- axis runs from 0 to 100 minutes in intervals of 10 minutes.
  • Figure 59 is a graph of cell retention versus time for the device of Figure 46A at two different frequencies, 1 MHz and 2 MHz. The darker circles are for 2 MHz.
  • the y-axis runs from 0.00 to 1 .00 in intervals of 0.10.
  • the x-axis runs from 0 to 300 minutes in intervals of 50 minutes.
  • Figure 60 is a graph of perfusate cell density (million cells/mL) versus time for the device of Figure 46A at two different frequencies, 1 MHz and 2 MHz. The darker circles are for 2 MHz.
  • the y-axis runs from 0.00 to 25.00 in intervals of 5.00.
  • the x- axis runs from 0 to 300 minutes in intervals of 50 minutes.
  • Figure 61 is a front cross-sectional view of a seventh exemplary embodiment of an acoustic perfusion device of the present disclosure.
  • Figure 62 is a front view photograph of a working 1 inch by 1 inch by 1 inch separator system using a 1 inch by 1 inch crystal to separate beads from a yeast mixture.
  • Figure 63 is a log-log graph showing the relationship of the MRC-5 radiation force, the Cytodex beads radiation force, gravity / buoyancy force, and Stokes' drag force to particle size. The horizontal axis is in microns (pm) and the vertical axis is in Newtons (N).
  • Figure 64 is a graph of viable cell density (VCD) (10 6 cells/mL) over time for specified AWS power (%) and specified harvest to recirculation ratios (%).
  • VCD viable cell density
  • the x-axis (culture day) runs from 0 to 30 days in intervals of 5 days.
  • the left-side y-axis (VCD) runs from 0 to 80x10 6 cells/mL in intervals of 1 before the break and intervals of 20 after the break, and is used for the circles.
  • the first right-side y-axis (AWS power) runs from 0 to 60 in intervals of 10, and applies to the line that starts at about 30% and ends at about 10%.
  • the second right-side y-axis (harvest to recirculation ratio) runs from 0.0 to 0.5 in intervals of 0.1 , and applies to the line that starts at about 0.15% and ends at 0.3%.
  • a vertical dashed line shows that AWS began on day 7. The darker line extending from the vertical dash line corresponds to the AWS power, and the lighter line extending from the vertical dashed line corresponds to the harvest to recirculation ratio.
  • the white dots represent the AWS harvest, and the black dots represent the bioreactor.
  • Figure 65 is a space characterization of the harvest to recirculation flow ratio (%) versus the AWS power (%).
  • the y-axis (harvest to recirculation flow ratio) runs from 0.2 to 1 .2 in intervals of 0.2.
  • the x-axis (AWS power) runs from 10 to 60 in intervals of 10.
  • Figures 66A-66C are graphs of AWS versus TFF mAb titer and product transmission. In all three graphs, AWS is diamonds, TFF with bleed is squares, and TFF without bleed is triangles.
  • Figure 66A shows the mAb titer on the y-axis versus the culture day on the x-axis. The production of the mAb titer is higher for the AWS than it is for the TFF where the cells are bled away.
  • Figure 66B is a graph comparing the transmission of monoclonal antibody (mAb) versus culture day. The y-axis is % transmission, and the x-axis is the culture day. The dotted line indicates 100% transmission.
  • mAb monoclonal antibody
  • FIG. 66C shows relative mAb residence time on the y-axis versus culture day on the x-axis.
  • the relative residence time for the mAb separated by AWS is lower than the relative residence time for the TFF with or without cell bleed.
  • Figure 67 is a graph of cell separation efficiency over time for AWS cell separation at a 10L scale.
  • the second left-side y-axis (bioreactor VCD) runs from 0 to 80x 1 0 6 cells/mL in intervals of 20.
  • the right-side y-axis runs from 0.0 to 1 .0 in intervals of 0.2, and is used for the top line.
  • the cell separation efficiency is a percentage (i.e., 0.2 corresponds to 20% efficiency, 0.6 corresponds to 60% efficiency, 1 .0 corresponds to 1 00% efficiency, etc.)
  • Figure 68A is a graph showing the relative abundance of high molecular weight (HMW) species, monomer species, and low molecular weight (LMW) species of a monoclonal antibody (mAb) after size exclusion chromatography (SEC). The darker bars represent the bioreactor, and the lighter bars represent the harvest.
  • Figure 68B is a graph showing the relative abundance of acidic, main peak, and basic species of a mAb after ion exchange chromatography (IEX). Again, the darker bars represent the bioreactor, and the lighter bars represent the harvest.
  • Figure 68C is a bar graph showing glycosylation of proteins, showing the proteins sent through the acoustic perfusion device do not differ from proteins sent through a TFF device.
  • BRX refers to the bioreactor
  • HARV indicates the harvested material.
  • Figures 69A-69B are graphs comparing the AWS process to a tangential flow filtration (TFF) perfusion process using a 0.22 micron membrane. The darker bars represent AWS and the lighter bars represent TFF.
  • Figure 69A shows the relative abundance of HMW species, monomer species, and LMW species of a mAb after size exclusion chromatography (SEC).
  • Figure 69B shows the relative abundance of acidic, main peak, and basic species of a mAb after IEX.
  • Figure 70 is a perspective view of an eighth exemplary embodiment of an acoustic perfusion device of the present disclosure. DETAILED DESCRIPTION
  • the modifier "about” used in connection with a quantity is inclusive of the stated value and has the meaning dictated by the context. When used in the context of a range, the modifier “about” should also be considered as disclosing the range defined by the absolute values of the two endpoints. For example, the range of “from about 2 to about 10” also discloses the range “from 2 to 10.”
  • the term “about” may refer to plus or minus 10% of the indicated number. For example, “about 10%” may indicate a range of 9% to 1 1 %, and “about 1 " may mean from 0.9-1 .1 .
  • the terms “upper” and “lower” are relative to each other in location, i.e. an upper component is located at a higher elevation than a lower component in a given orientation, but these terms can change if the device is flipped.
  • the terms “inlet” and “outlet” are relative to a fluid flowing through them with respect to a given structure, e.g. a fluid flows through the inlet into the structure and flows through the outlet out of the structure.
  • upstream and “downstream” are relative to the direction in which a fluid flows through various components, i.e. the flow fluids through an upstream component prior to flowing through the downstream component. It should be noted that in a loop, a first component can be described as being both upstream of and downstream of a second component.
  • top and bottom are used to refer to surfaces where the top is always higher than the bottom/base relative to an absolute reference, i.e. the surface of the earth.
  • upwards and “downwards” are also relative to an absolute reference; upwards is always against the gravity of the earth.
  • the present application refers to "the same order of magnitude.” Two numbers are of the same order of magnitude if the quotient of the larger number divided by the smaller number is a value of at least 1 and less than 10.
  • Bioreactors are useful for making biomolecules such as recombinant proteins or monoclonal antibodies. Very generally, cells are cultured in a bioreactor vessel with media in order to produce the desired product, and the desired product is then harvested by separation from the cells and media in an acoustic perfusion device, such as the device of the present disclosure.
  • the acoustic filtering device permits the withdrawal of some desired product, a small portion of the media, and cellular fragments / debris smaller than the cells, with the remainder being recycled back to the bioreactor (particularly the cells).
  • mammalian cell cultures including Chinese hamster ovary (CHO), NSO hybridoma cells, baby hamster kidney (BHK) cells, insect cells, and human cells (e.g. T-cells, B-cells, stem cells, red blood cells), and living/biological cells in general has proven to be a very efficacious way of producing/expressing the recombinant proteins and monoclonal antibodies used in various applications such as pharmaceuticals or vaccines.
  • a perfusion bioreactor may also be utilized to generate cells that would be utilized in a cell therapy process.
  • biological cells such as CAR T-cells, Jurkat T-cells and the like are cultured in a perfusion bioreactor.
  • the acoustic standing wave used in the perfusion devices of the present disclosure can be used to separate viable and nonviable cells after the transfection process. This separation ability allows for improved efficacy of the inoculation of the patient with this T-cell therapy, since viable cells may be primarily utilized.
  • the nonviable cells and cell fragments are separated out through the perfusion process, with these materials going into the secondary flow and exiting the bioreactor.
  • a perfusion bioreactor may also be used for production of exosomes, microvesicles, or vesicles by cells.
  • the acoustic perfusion device can then be used to harvest the exosomes, or other desired cell products, or other targets in a host fluid.
  • a perfusion bioreactor can be used to produce viruses, such as lentivirus, which are used in cell and gene therapy to transfect cells.
  • the acoustic perfusion device can then be used to harvest the virus. In all cases, the device is a cell retention device.
  • Perfusion bioreactors are particularly attractive because of the continuous production of the biomolecules from the expressing cell culture, and shorter residence time of said biomolecules in the process prior to harvest.
  • the target cells are held back by a filtration process, such as tangential flow filtration (TFF) or alternating tangential flow filtration (ATF) while the expressed biomolecules are extracted from the perfusion bioreactor.
  • the cells are returned to the bioreactor to receive the nutrition and oxygen to maintain the production of the overall cell culture.
  • the cells continue to multiply, and some cells may be removed or bled off from the cell culture population throughout the perfusion production process.
  • TFF and ATF processes of filtration have several issues, such as clogging/fouling and loss of biomolecule product (particularly at high cell densities), all directly related to the nature of the hollow fiber membranes used in the filtration. It is therefore desirable to find a new filtration process that does not clog and minimizes loss of the desired biomolecule product.
  • TFF and ATF will retain all cellular debris and fines within the bioreactor, which is not desirable. A process capable of distinguishing between cell retention while allowing for the passing of cell debris and fines may therefore be favorable.
  • the present disclosure relates to acoustic perfusion devices capable of generating multi-dimensional acoustic standing wave(s) from one or more piezoelectric transducers, where the transducers are electrically excited such that they move in a multi-mode displacement pattern rather than a "piston" mode of vibration.
  • acoustic standing wave generation a higher lateral trapping force is generated than if the piezoelectric transducer is excited in a "piston" mode where one large standing wave is generated.
  • the multi-dimensional acoustic standing waves can have a higher lateral trapping force compared to a planar acoustic standing wave.
  • the input power is tunable for a controlled flow.
  • This tunability can be used to facilitate proteinaceous fluid purification of a fluid stream coming from a bioreactor.
  • the acoustic standing wave may also be a planar standing wave where the piezoelectric transducer is excited in the piston mode, generating a planar wave.
  • the acoustic standing wave(s) may also be a combination of planar and multi-dimensional acoustic standing waves. All of these standing waves generate an "interface effect" such that the cells from the bioreactor are held back and the biomolecule product expressed from the cells, cell fragments and small debris are allowed to pass through.
  • Acoustophoresis is a low-power, no-pressure-drop, no-clog, solid-state approach to particle separation from fluid dispersions (i.e., it is used to achieve separations that are more typically performed with porous filters, but it has none of the disadvantages of filters).
  • the acoustic perfusion devices of the present disclosure are suitable for use with macro-scale bioreactors for separations in flowing systems with high flow rates.
  • the acoustic perfusion device is designed to create a high intensity multi-dimensional ultrasonic standing wave that results in an acoustic radiation force that can overcome the combined effects of fluid drag and buoyancy or gravity at certain flow rates.
  • the radiation force acts as a filter that prevents targeted particles (e.g., biological cells) from crossing through the standing wave.
  • targeted particles e.g., biological cells
  • the trapping capability of a standing wave may be varied as desired, for example by varying the flow rate of the fluid, the acoustic radiation force, and the shape of the acoustic filtering device to maximize cell retention through trapping and settling.
  • This technology offers a green and sustainable alternative for separation of secondary phases with a significant reduction in cost of energy. Excellent particle separation efficiencies have been demonstrated for particle sizes as small as one micron.
  • an acoustic standing wave generates pressure minima at locations on the standing wave where the amplitude is minimum and maximum. These are called, respectively, nodes and anti-nodes. These pressure minima nodes and anti- nodes may be utilized to capture materials that are differentiated from the surrounding environment by size, density and compressibility (i.e., the speed of sound through the material). Those materials that collect at the pressure minima nodes are known as having a positive contrast factor. Those materials that collect at the pressure minima anti-nodes are known as having a negative contrast factor.
  • the system is driven such that the particles are trapped in the ultrasonic standing wave, i.e., remain in a stationary position.
  • the axial component of the acoustic radiation force drives the particles, with a positive contrast factor, to the pressure nodal planes, whereas particles with a negative contrast factor are driven to the pressure anti-nodal planes.
  • the radial or lateral component of the acoustic radiation force is the force that contributes to trapping the particle.
  • the forces acting on the particle may be greater than the combined effect of fluid drag force and gravitational force.
  • the scattering of the acoustic field off the particles results in a three-dimensional acoustic radiation force, which acts as a three-dimensional trapping field.
  • the acoustic radiation force is proportional to the particle volume (e.g., the cube of the radius) when the particle is small relative to the wavelength.
  • the force is proportional to frequency and the acoustic contrast factor.
  • the force also scales with acoustic energy (e.g., the square of the acoustic pressure amplitude).
  • the sinusoidal spatial variation of the force is what drives the particles to the stable positions within the standing waves.
  • the particle When the acoustic radiation force exerted on the particles is stronger than the combined effect of fluid drag force and buoyancy/gravitational force, the particle is trapped within the acoustic standing wave field.
  • the action of the lateral and axial acoustic forces on the trapped particles results in formation of tightly packed clusters through concentration, clustering, clumping, agglomeration and/or coalescence of particles that, when reaching a critical size, settle continuously through enhanced gravity for particles heavier than the host fluid or rise out through enhanced buoyancy for particles lighter than the host fluid.
  • secondary inter-particle forces such as Bjerkness forces, aid in particle agglomeration. Relatively large solids of one material can thus be separated from smaller particles of a different material, the same material, and/or the host fluid through enhanced gravitational/buoyancy separation.
  • the axial acoustic radiation force drives the cells towards the standing wave pressure nodes.
  • the axial component of the acoustic radiation force drives the cells, with a positive contrast factor, to the pressure nodes, whereas cells or other particles with a negative contrast factor are driven to the pressure anti-nodes.
  • the radial or lateral component of the acoustic radiation force is the force that traps the cells.
  • the radial or lateral component of the ARF is larger than the combined effect of fluid drag force and gravitational force. For small particles or emulsions, the drag force F D and Stokes' drag F S D can be expressed as:
  • Uf and U p are the fluid and particle velocity
  • R p is the particle radius
  • f and ⁇ ⁇ are the dynamic viscosity of the fluid and particle, respectively
  • ⁇ ⁇ ⁇ I ⁇ ⁇ is the ratio of dynamic viscosities
  • V s is the particle settling velocity given where p f is the fluid density, p p is the particle density, and g is the universal gravitational constant.
  • ⁇ is the acoustic pressure
  • u is the fluid particle velocity
  • ⁇ is the ratio of cell density p p to fluid density p f
  • ⁇ is the ratio of cell sound speed c p to fluid sound speed Cf
  • ⁇ > indicates time averaging over the period of the wave.
  • F A RF the axial component of the acoustic radiation force
  • Particles with a positive contrast factor will be driven to the pressure nodal planes, and particles with a negative contrast factor will be driven to the pressure anti- nodal planes.
  • the generation of a multi-dimensional acoustic standing wave in a flow chamber results in the creation of tightly packed clusters of particles in the flow chamber, typically corresponding to the location of the pressure nodes or anti-nodes in the standing wave depending on acoustic contrast factor.
  • Gork'ov's model is for a single particle in a standing wave and is limited to particle sizes that are small with respect to the wavelength of the sound fields in the fluid and the particle. It also does not take into account the effect of viscosity of the fluid and the particle on the radiation force. As a result, this model cannot be used for the macro-scale ultrasonic separators discussed herein since particle clusters can grow quite large. A more complex and complete model for acoustic radiation forces without any restriction as to particle size relative to wavelength was therefore used. The models that were implemented are based on the theoretical work of Yurii llinskii and Evgenia Zabolotskaya as described in AIP Conference Proceedings, Vol. 1474-1 , pp.
  • a n ,m and a( n -n, m ) are the expansion coefficients of external field potential with respect to spherical functions j n (kr)Y n ,m(Q, ⁇ P), Y n ,m(Q, ⁇ P) are spherical harmonies,
  • a n is the scattering coefficient for mode (m,n)
  • K is bulk modulus
  • k is the wavenumber in the liquid.
  • the target biological cells are generally at lower concentrations than, for example, a CHO cell population with 30 million cells per mL versus a concentration of 1 million cells per mL for Jurkat T cells.
  • the low contrast cells such as Jurkat T cells, in a low population concentration are separated continuously from the fluid media within which they are entrained by utilizing a multi-dimensional acoustic standing wave.
  • the ultrasonic transducer(s) generates a multi-dimensional standing wave in the fluid that exerts a lateral force on the suspended particles to accompany the axial force.
  • the multi-dimensional standing wave generates acoustic radiation forces in both the axial direction (e.g., in the direction of the standing wave, between the transducer and the reflector, which may be at an angle across the flow direction, and in some instances may be perpendicular to the flow direction) and the lateral direction (e.g., in the flow direction or transverse to the direction between the transducer and the reflector).
  • the axial direction e.g., in the direction of the standing wave, between the transducer and the reflector, which may be at an angle across the flow direction, and in some instances may be perpendicular to the flow direction
  • the lateral direction e.g., in the flow direction or transverse to the direction between the transducer and the reflector.
  • this acoustic force is across (e.g. perpendicular to) the flow direction and the drag force, it quickly moves the particles to pressure nodal planes or anti-nodal planes, depending on the contrast factor of the particle.
  • the lateral acoustic radiation force acts to move the concentrated particles towards the center of each planar node, resulting in clustering, agglomeration or clumping.
  • the lateral acoustic radiation force component can overcome fluid drag for such clumps of particles, to continually grow the clusters, which can exit the mixture due to gravity or buoyancy.
  • the drop in drag per particle as the particle cluster increases in size, as well as the drop in acoustic radiation force per particle as the particle cluster grows in size, may separately or collectively influence operation of the acoustic separator device.
  • the lateral force component and the axial force component of the multi-dimensional acoustic standing wave are of the same or different order of magnitude.
  • the ratio of the lateral force component to the axial force component is about 0.5 or less.
  • the axial force is stronger than the lateral force, but the lateral force of such a multi-dimensional acoustic standing wave is much higher than the lateral force of a planar standing wave, usually by two orders of magnitude or more.
  • Typical results published in literature state that the lateral force is two orders of magnitude smaller than the axial force.
  • the technology disclosed in this application provides for a lateral force to be of the same order of magnitude as the axial force.
  • the device use both transducers that produce multi-dimensional acoustic standing waves and transducers that produce planar acoustic standing waves.
  • a standing wave where the lateral force is not the same order of magnitude as the axial force is considered a "planar acoustic standing wave.”
  • the lateral force component of the total acoustic radiation force (ARF) generated by the ultrasonic transducer(s) of the present disclosure is significant and is sufficient to overcome the fluid drag force at linear velocities of up to 1 cm/s, and to create tightly packed clusters, and is of the same order of magnitude as the axial force component of the total acoustic radiation force.
  • the average size of microvesicles such as exosomes (i.e., about 150 nanometers in diameter or smaller), makes it difficult to separate the same using normal acoustophoretic techniques.
  • the acoustic footprint or contrast factor of the exosomes may be increased dramatically by functionalizing the surface of the bead such that it will attach to the exosomes and create a moiety that is subject to acoustophoresis through its high contrast factor.
  • the beads may have either a positive or negative contrast factor.
  • Positive contrast factor materials include polystyrene beads, glass beads and other materials whose density is greater than that of the host fluid that contains the exosomes.
  • Negative contrast factor materials of interest include microbubbles, micro-glass spheres and other low-density beads that may be functionalized to attract exosomes and thus increase their contrast factor footprint.
  • the functionalization of the beads may be by, for example, attachment of CD 9, CD 63, CD 81 , or EP CAM.
  • the acoustophoresis separation processes of the present disclosure may be coupled with other techniques, such as field flow fractionation where the ultrasonic wave is utilized to fractionate the materials entrained in a fluid stream, such as the exosome moieties or the beads that are carrying the exosomes through affinity binding.
  • the acoustophoresis separation processes of the present disclosure may also be coupled with tangential flow filtration in a flow field that is bounded by the acoustic standing wave.
  • Figure 40 shows two prior art filtration methods.
  • the left- hand side of Figure 40 illustrates direct flow filtration (DFF).
  • DFF direct flow filtration
  • the filter 4010 holds back the particles 4020 that are larger than the filter's pore size, whereas smaller particles 4030 and the fluid pass through the filter.
  • the right-hand side of Figure 40 illustrates tangential flow filtration (TFF).
  • TFF tangential flow filtration
  • the feed stream is not directed towards the filter. Rather, the feed stream is directed tangentially to the filter, such that a majority of the feed stream passes tangentially over the filter surface.
  • this feed stream is recirculated to pass by the filter more than once.
  • a much smaller filtrate stream 4006 is pulled through the filter membrane containing the smaller particles 4030.
  • the fluid ensonified by the acoustic standing wave is clarified by the process of trapping cells and growing them into tightly packed clusters, such that continuous gravitational separation of the clusters of cells takes place. Since there is a limited amount of new cells flowing into this volume, this results in a rapid clarification of the fluid subjected to the acoustic standing wave.
  • the system can be described as including two fluids: a first fluid containing the desired product and small cell fragments / debris (which have passed through the acoustic standing wave), and a second fluid containing the bioreactor fluid and all of the cells (which are held back by the acoustic standing wave).
  • the two fluids may be of different effective acoustic properties, such as density and speed of sound, with a well-defined interface between these two fluids.
  • the acoustic standing wave is a three-dimensional acoustic field, which, in the case of excitation by a rectangular transducer, can be described as occupying a roughly rectangular prism volume of fluid.
  • two opposing faces are the transducer and reflector, an adjacent pair of opposing faces are the walls of the device, and the final opposing pair of faces, the upstream and downstream faces of the cube, extend through the fluid.
  • the interface between the two fluids is generally located near the upstream face of the acoustic standing wave field, generating an "acoustic barrier or edge effect".
  • the first fluid i.e., the fluid that has been clarified and contains the product, some cells, and cell fragments
  • the second fluid i.e., the fluid containing the bioreactor fluid and most of the cells
  • the interface effect location may move downstream and is then located within the volume of fluid ensonified by the transducer.
  • the acoustic standing wave field exerts an acoustic radiation pressure (i.e. a pressure rise) and an acoustic radiation force on the cells at the interface region between the two fluids, thereby keeping the upstream cells from entering the acoustic field.
  • the occurrence of the radiation pressure and the force on the interface allows for the first fluid containing the product to pass through the interface while retaining the cells in the upstream fluid.
  • the cells that are held back by the effect of the acoustic radiation force at the interface between the two fluids can be continuously returned to the bioreactor to ensure they receive the nutrition and oxygen to maintain the production of the overall cell culture.
  • the circulating motion of the flow field underneath the interface transports the cells that are retained by the acoustic field back to the bioreactor.
  • the circulating flow motion is driven by the primary recirculation stream and can be optimized with acoustic chamber geometry variations for maximum system efficiency. This process or configuration is discussed further below with respect to Figure 33.
  • the acoustic perfusion devices of the present disclosure have multiple possible modes of operation. One of these modes may be dominant in the device or they may occur concurrently depending on the distribution of cells and fluid within the device.
  • a first mode of operation illustrated in Figure 41 (Mode 1 )
  • the fluid containing larger particles 4020 enters the acoustic standing wave field 4040, which is produced here between transducer 4008 and reflector 4009.
  • a multidimensional acoustic standing wave traps the particles at specific points, packs the particles into tightly packed clusters 4022, and continuously separates the clusters through enhanced gravitational settling.
  • the particle clusters settle out, enter the tangential flow path (indicated by arrow 4001 ) and are redirected to the bioreactor by the recirculation stream.
  • Smaller particles 4030 (darker color) are not trapped by, and pass through, the acoustic standing wave, to be harvested.
  • the harvest flow direction is indicated by arrow 4002.
  • the orientation of this device is significant, and the direction of gravity is also indicated.
  • the larger particles 4020 can be cells and the smaller particles 4030 can be cell debris and/or fines.
  • the larger particles 4020 can be beads and the smaller particles 4030 can be cells or exosomes (or more generally the desired target material).
  • the larger particles 4020 can be beads with attached antibodies and the smaller particles 4030 can be cells that are not targeted by the functional ized beads.
  • the second mode of operation (Mode 2) is illustrated in Figure 42, where the acoustophoretic system creates a strong barrier for cells at the interface between the two fluids and prevents cells from entering the acoustic field.
  • a barrier of cells is established between the two fluids through the interface effect of the acoustic standing wave.
  • a first clarified fluid stream 4050 contains the smaller particles / desired byproducts 4030 within the acoustic standing wave field and the harvest stream.
  • a second fluid stream 4055 contains the retained cells 4020 upstream of the acoustic standing wave field.
  • the harvest flow direction is indicated by arrow 4002.
  • an acoustic interface effect is realized, as indicated by dotted line 4007 (representing the interface region between the two fluids, clarified fluid downstream and flow mixture and cells on the upstream side).
  • the acoustic interface effect holds the cells back and prevents them from entering the acoustic field while a portion of the fluid stream containing the produced biomolecules and cell fragments is permitted to pass through this barrier.
  • the tangential flow path underneath the acoustic interface (arrow 4001 ) collects the retained cells and flows them back into the main recirculation stream and back to the bioreactor. This recirculation is discussed further below with respect to Figure 32 and Figure 61. Again, the direction of gravity is indicated in the figures.
  • the second fluid stream 4055 can contain desired target material which is retained within the perfusion device, and the first fluid stream 4050 can be returned to the bioreactor.
  • the setup of the acoustophoretic device is similar to that of TFF.
  • a feed stream containing the cells, cell debris, fines, and product, i.e., protein flows from the bioreactor into the perfusion system.
  • a portion of the stream flows in a tangential fashion along the upstream / lower interface region of the acoustic standing wave and is recirculated back to the bioreactor.
  • a smaller portion of the feed stream is harvested, i.e., diverted and flows through the acoustic standing wave.
  • the acoustic standing wave functions very similarly to the filter in TFF, preventing the cells from entering the acoustic field.
  • the harvest stream contains smaller particles such as cell debris and fines as well as the desired biomolecule product.
  • the cells that are retained by the acoustic standing wave are transported by the recirculation stream back to the bioreactor.
  • Figure 32 and Figure 61 which are discussed further herein, also illustrate perfusion devices that use a tangential flow stream.
  • Perfusion applications typically entail high cell densities, e.g., > 50 million cells/mL, and lower harvest velocities contrary to cell clarification or oil/water applications.
  • the two fluid streams also have different effective acoustic properties, i.e., speed of sound and density of the media/cell mixture. As cell density increases, the difference in acoustic properties of the two fluid streams are more pronounced.
  • the acoustic standing wave field exerts an acoustic radiation pressure, i.e., a pressure rise, on the second fluid stream, enriched with cells, as well as acoustic radiation forces on the cells suspended in the fluid.
  • This radiation pressure and radiation force act at the interface between the two fluids which coincides with the upstream bounding surface of the acoustic field.
  • this "acoustic interface" effect of acoustic radiation force is sufficiently strong, it can prevent the cells from entering the acoustic field. Equally important is a tangential flow path to collect the retained cells and transport them back to the bioreactor.
  • the acoustic interface effect may also be referred to as an acoustic wall effect and results from the interface of the acoustic field exerting a strong lateral force (i.e., in the opposite direction to the harvest flow and perpendicular to the axis of the acoustic standing wave) on the suspended particles, thereby keeping the relatively larger sized particles from entering the acoustic field and allowing clarified fluid (i.e., the fluid containing the smaller-sized product) to enter the acoustic field, thereby creating an acoustic perfusion cell retention device. In this way, the clarified fluid can escape and the cells are held down by the radiation force.
  • a strong lateral force i.e., in the opposite direction to the harvest flow and perpendicular to the axis of the acoustic standing wave
  • the cells that are held back by the acoustic radiation force may then picked up by the scrubbing motion of the fluid flow field (i.e., the recirculating flow underneath the interface), and be continuously returned to the bioreactor to ensure they receive the nutrition and oxygen to maintain the production of the overall cell culture.
  • the clarified fluid contains both the desired products and cell fragments, all of which are smaller than whole viable cells. In this way, the media that is returned to the bioreactor is clarified of cell fragments. Cell fragments absorb media without producing desired product, making the perfusion process less efficient. Thus, there is an efficiency gain and a cost savings obtained by removing these cell fragments using the acoustic perfusion devices of the present disclosure.
  • Further clarification of the clarified fluid may be achieved downstream using a second device or a secondary flow chamber that contains another transducer-reflector pair that operates at a different frequency.
  • This arrangement traps, clumps, clusters, or agglomerates particles having a size of about 10 microns or less that may have passed through the original acoustic standing wave, in the same manner as described before.
  • a third transducer-reflector pair operating at another frequency, 3 MHz to 20 MHz, or higher, may be utilized to trap, clump, cluster, or agglomerate and drop out the small cell fragments and debris that passed through the initial acoustic standing wave and the "interface effect".
  • This triple- clarified fluid containing the desired biomolecules can then directly enter a sterile filter.
  • the original acoustic perfusion device may operate at frequencies up to about 4 MHz. It is contemplated that the frequency of this second and third acoustic standing wave field would be from about 6 MHz to about 20 MHz, and possibly higher, to trap smaller sized cell fragments.
  • an instability usually manifested as a perturbation or oscillation of the interface between the two fluids, may grow sufficiently strong such that cells enter the volume of fluid within the acoustic standing wave, at which point, for a short period of time, the device acts in a combined mode of operation, where both modes are active (i.e., the interface effect prevents cells from entering the acoustic field as explained above, while the acoustic field clarifies the cells that have entered the volume of fluid within the acoustic standing wave field).
  • the mode of operation is then again that of the second described mode of operation, namely, the acoustic interface effect.
  • the device can operate in both/either of the modes of operation, as described above, without external switching.
  • the properties of the fluid streams e.g., cell concentrations in the streams, and acoustic field dictate which mode dominates.
  • acoustic standing wave(s) perfusion devices of the present disclosure are operated differently compared to prior acoustic filter usages, previously described in literature.
  • acoustophoresis was operated such that the protein-producing materials, such as Chinese hamster ovary cells (CHO cells), the most common host for the industrial production of recombinant protein therapeutics, were trapped within a planar ultrasonic standing wave (i.e., remain in a stationary position). Cells were retained in an acoustic field by causing individual cells to migrate towards the pressure nodal planes of the planar acoustic standing wave.
  • CHO cells Chinese hamster ovary cells
  • the ultrasonic standing waves are used as a blanket or selector or "force field" in the perfusion device.
  • the perfusion device is configured to permit fluid flows that are against gravity forces. The flows against gravity contribute to the biological cells sinking.
  • the standing wave is created near the top of the filtering device and acts like a filter to prevent the cells from entering the acoustic field and exiting through the top of the filtering device (i.e., acting similar to a force field holding the cells back from entering the acoustic field).
  • the acoustic perfusion device has two fluid streams flowing at different rates.
  • the main fluid stream carrying the expressing cell culture, culture media, product, and other bioreactor constituents, enters the device and is partially diverted into a secondary, lower volume, lower flow fluid stream.
  • This secondary fluid stream passes through the multi-dimensional acoustic standing wave, where the multi-dimensional acoustic standing wave (or generally the interface effect created by the acoustic standing wave) holds back the main cell culture and allows the expressed biomolecules, the monoclonal antibodies and recombinant proteins, along with other small particles such as submicron and micron-sized cell debris, to pass through and be further collected and processed outside / downstream of the bioreactor.
  • the main fluid stream, containing the main cell culture, is then recycled back to the bioreactor.
  • the acoustic standing wave and its "interface effect" can be considered to act as a filter, preventing large cells, other particles or bodies, from exiting the bioreactor.
  • the acoustic perfusion devices can act as a retention device and cell washing device for cell therapy applications.
  • continuous cell-culture applications such as autologous and allogeneic cell therapy
  • cells may be initially harvested at a very low cell-density.
  • the cells may be purified, isolated and proliferated in the cell culture. Relatively few cells may be used to seed a bioreactor.
  • the bioreactor may be used to increase the number of cells in the cell culture. Further processing steps such as concentrating, washing, and media exchange are all needed for various applications.
  • the commonality in all these applications is the need to continuously circulate, add, and/or remove media while retaining cells in a bioreactor (which may be traditional or single-use) with no effect to their viability.
  • the acoustic cell retention systems described herein operate over a range of cell recirculation rates, efficiently retain cells over a range of perfusion (or media removal rates), and can be tuned to fully retain or selectively pass some percentage of cells through fluid flow rate, transducer power or frequency manipulation. Power and flow rates can all be monitored and used as feedback in an automated control system. Specialty flow paths may also be used such that a small volume of the main fluid flow is "sipped" off and the expressed biomolecules are separated from the main cell culture.
  • acoustophoresis is that the acoustic radiation force does not harm or negatively affect the biological cells or the desired biomolecule product. Moreover, perfusion is continuous, such that the cell culture is kept viable and desired products can be continually recovered therefrom.
  • a perfusion bioreactor system it is desirable to be able to filter and separate the viable biological cells from the expressed materials that are in the fluid stream (i.e., cell culture media) and cellular debris.
  • biological cells may include Chinese hamster ovary (CHO) cells, whose cell genome is manipulated to express large biomolecules.
  • biomolecules can include recombinant proteins or monoclonal antibodies, and are the desired product to be recovered.
  • the acoustic perfusion devices of the present disclosure are designed to maintain a high intensity multi-dimensional acoustic standing wave that can act as a filter, permitting smaller particles (such as recombinant proteins or cellular debris) to pass through while excluding larger particles (such as viable cells).
  • the device is driven by an oscillator and amplifier (not shown), and the device performance is monitored and controlled by a computer (not shown).
  • the parameters of the energy or signal applied to the transducer such as, for example, frequency or voltage amplitude, may be controlled and/or modulated. In some instances it may be desirable to control the applied signal to compensate for effects such as acoustic streaming. This control may be achieved by amplitude modulation and/or by frequency modulation.
  • the duty cycle of the propagation of the standing wave may also be utilized to achieve certain results (i.e. the acoustic beam may be turned on and shut off at different time periods or rates).
  • Figure 63 is a log-log graph (logarithmic y-axis, logarithmic x-axis) that shows the scaling of the radiation forces of cells (MRC-5) and microcarriers (Cytodex beads), fluid drag force, and buoyancy force with particle radius.
  • the graph provides an explanation for the separation of microvesicles, cells or microcarriers from a host fluid based on parameter settings. For example, the frequency, flow rate (drag force) and power can be controlled and/or modulated to prevent or permit passage of microvesicles, cells or microcarriers.
  • the drag force intersection with the radiation force curves rises along the curves and can pass the point where particles the size of Cytodex beads are repelled, so that microvesicles, cells and beads are all passing through the acoustic field.
  • cells and microvesicles are passed, while the beads are repelled.
  • Lowering the fluid flow until the intersection of the drag force line intersection with the radiation force curves is below the cell (MRC5) size causes microvesicles (which are smaller than cells and not shown on the graph) to pass, while cells and beads are repelled or retained by the acoustic field. Similar effects can be achieved by modulating and/or controlling frequency or power of the acoustic field.
  • the perfusion systems disclosed herein can discriminate based on size with a relatively high level of distinction.
  • Figure 1 illustrates a single standing wave system 100 that is comprised of a reflector plate 101 and an ultrasonic transducer 103 that is set to resonate so as to form a standing wave 102.
  • Excitation frequencies typically in the range from 100 kHz to 100 MHz are applied by the transducer 103.
  • One or more multi-dimensional standing waves are created between the transducer 103 and the reflector 101.
  • An ideal standing wave is the sum of two propagating waves that are equal in frequency and intensity and that are traveling in opposite directions, i.e. from the transducer to the reflector and back. The propagating waves constructively interfere with each other and thus generate the standing wave.
  • a dotted line 105 is used to indicate the zero-amplitude of the wave.
  • a node is a point where the wave has minimum amplitude, and is indicated with reference numeral 107.
  • An anti-node is a point where the wave has maximum amplitude, and is indicated with reference numeral 109.
  • the standing wave is illustrated as beginning and ending with local maxima, however, other implementations are possible.
  • the standing wave can be offset at the transducer or the reflector so that local minima or maxima are spaced from the transducer or from the reflector.
  • the reflected wave (or wave generated by an opposing transducer) can be in- or out-of-phase with the transducer generated wave.
  • the characteristics of the standing wave can be modified and/or controlled by the drive signal applied to the transducer, such as by modifying and/or controlling the phase, amplitude, or frequency of the drive signal.
  • Acoustically transparent or responsive materials may also be used with the transducer or reflector to modify and/or control the standing wave.
  • FIG. 2 is a schematic diagram that compares a fed-batch bioreactor system 201 (left side) with a perfusion bioreactor system 202 (right side).
  • the bioreactor 210 includes a reaction vessel 220.
  • the cell culture media is fed to the reaction vessel through a feed inlet 222.
  • An agitator 225 is used to circulate the media throughout the cell culture.
  • the agitator is depicted as a set of rotating blades, though any type of system that causes circulation is contemplated.
  • the bioreactor permits growth of a seed culture through a growth / production cycle, during which time debris, waste and unusable cells will accumulate in the bioreactor and the desired product (e.g.
  • the reaction vessel 220 also includes an outlet 224 for removing material.
  • the bioreactor includes a reaction vessel 220 with a feed inlet 222 for the cell culture media.
  • An agitator 225 is used to circulate the media throughout the cell culture.
  • An outlet 224 of the reaction vessel is fluidly connected to the inlet 232 of an acoustic perfusion device 230 of the present disclosure, and continuously feeds the bioreactor contents (containing cells and desired product) to the filtering device.
  • the perfusion device is located downstream of the reaction vessel, and separates the desired product from the cells.
  • the acoustic perfusion device 230 has two separate outlets, a product outlet 234 and a recycle outlet 236.
  • the product outlet 234 fluidly connects the acoustic perfusion device 230 to a containment vessel 240 downstream of the perfusion device, which receives the flow of the desired product (plus media) from the perfusion device. From there, further processing / purification can occur to isolate / recover the desired product. For example, further downstream of this acoustic perfusion device may be additional filters such as an ATF, TFF, depth filter, centrifuge, etc.
  • the recycle outlet 236 fluidly connects the acoustic perfusion device 230 back to a recycle inlet 226 of the reaction vessel 220, and is used to send the cells and cell culture media back into the reaction vessel for continued growth / production. Put another way, there is a fluid loop between the reaction vessel and the perfusion device.
  • the reaction vessel 220 in the perfusion bioreactor system 202 has a continuous throughput of product and thus can be made smaller.
  • the filtering process is critical to the throughput of the perfusion bioreactor. A poor filtering process implies low throughput and results in low yields of the desired product.
  • FIG. 3 is a cross-sectional view of a generic bioreactor 300 that is useful for the systems of the present disclosure.
  • the bioreactor includes a reaction vessel 320 having an internal volume 323.
  • a feed inlet 322 at the top of the vessel is used to feed cell culture media into the vessel.
  • An agitator 325 is present.
  • An outlet 324 is shown at the bottom of the vessel.
  • a thermal jacket 310 surrounds the reaction vessel, and is used to regulate the temperature of the cells / media.
  • An aerator 312 is located on the bottom of the vessel for providing gas to the internal volume.
  • Sensors 314 are shown at the top right of the vessel.
  • a pump 316 is illustrated for feeding the cell culture media into the vessel, as is another pump 318 for removing cell culture media from the vessel.
  • the perfusion systems described above use an acoustic perfusion device of the present disclosure.
  • the contents of the bioreactor are continuously flowed through the acoustic perfusion device to capture the desired products.
  • Figure 4 is a first embodiment of an acoustic perfusion device 400 that can be used with the previously-described systems.
  • the device includes an inlet port 410, an outlet port 430, a first collection port 470, a bottom wall 420, and an acoustic chamber 450.
  • the acoustic chamber 450 can also be referred to as a fluid cell.
  • the inlet port 410 is located at a first end 412 of the device. Generally, the inlet port 410 is fluidly connected to an associated bioreactor and serves as the inlet through which the fluid mixture with cells, fines, and product is introduced to the device.
  • An inlet flow path 451 leads from the inlet port 410 to the acoustic chamber 450, which contains an internal volume.
  • An upper wall 411 can be present above the inlet flow path leading from the inlet port to the acoustic chamber, the upper wall having a substantially horizontal orientation.
  • the inlet flow path has a cross-sectional area 452 (illustrated by the dotted square).
  • the inlet port 410 is located at a first height 402 above the outlet port 430, which defines a bottom end of the device. Put another way, the outlet port 430 is located below the acoustic chamber 450 or below the inlet port 410, or at the bottom end 416 of the device. The placement of the outlet port 430 below the inlet port 410 ensures that fluid flow through the device is passively urged by gravity towards the outlet port 430, and that a hydraulic head is created within the device.
  • the outlet port 430 may also be referred to as a fluid recycle port because the host fluid is recycled or returned from the device to the associated bioreactor through the outlet port 430.
  • the outlet port 430 is also located at a second end 414 of the device, opposite the first end 412.
  • the first end 412 and second end 414 can be considered as being opposite ends of an x-axis, while the bottom end 416 and top end 418 can be considered as being opposite ends of a z-axis.
  • the first collection port 470 is located above the acoustic chamber 450 at the top end 418 of the device, and is fluidly connected to the acoustic chamber.
  • the device may include additional collection ports, such as second collection port 472, which is spaced apart from the first collection port 470.
  • the first and second collection ports 470, 472 are generally used to harvest and recover a portion of the desired biomolecule byproducts from the device.
  • a collection or harvest flow path 453 leads from the acoustic chamber to the collection ports 470, 472.
  • the collection flow path has a cross- sectional area 454 (illustrated by the dotted square).
  • the cross-sectional area 454 of the collection flow path is greater than the cross- sectional area 452 of the inlet flow path.
  • This arrangement provides one method by which the flow rate of fluid through the collection ports 470, 472 can be made much lower than the incoming flow rate of fluid.
  • the collection ports can also be referred to as perfusion or harvest ports. Because fluid depleted in cells and enriched in desired biomolecule products, cell debris, and other fines is harvested, the collection ports can also be referred to as harvest ports, and the collection flow path can also be referred to as the harvest flow path.
  • the bottom wall 420 extends from the inlet port 410 to the outlet port 430 of the device.
  • the exact shape of the bottom wall 420 can vary to obtain the desired fluid flow.
  • the bottom wall 420 curves from the inlet port 410 to the outlet port 430 of the device. Relative to a line between the inlet port 410 and the outlet port 430, illustrated as dotted line 401 , the bottom wall 420 has a concave curve.
  • An outlet flow path 432 leads from the acoustic chamber 450 to the outlet port 430
  • a first ultrasonic transducer 460 is located on a sidewall 440 of the device at a second height 404 that is above the first height 402 (i.e. closer to the top end 418 of the device) and below the collection ports 470, 472.
  • This volume above the acoustic chamber 450 and below the collection ports 470, 472 is identified here as a harvest or collection zone 456.
  • the first ultrasonic transducer 460 includes a piezoelectric material that can be driven by a drive signal to create a multi-dimensional standing wave in the acoustic chamber 450 across the collection flow path 453. An acoustic radiation force field thus separates the acoustic chamber 450 from the collection ports 470, 472.
  • the device includes a reflector 480 located on a wall opposite from the first ultrasonic transducer 460.
  • the reflector is also located at the second height (i.e. the same height as the transducer).
  • the transducer 460 and reflector 480 generate a multi-dimensional acoustic standing wave, as illustrated in Figure 1.
  • the inlet port 410, outlet port 430, and the collection ports 470, 472 are, in this illustrated embodiment, all located on a front wall 475 of the device. It is also contemplated that these ports can face in any other direction, as desired.
  • the front wall 475 is illustrated here as having a flat or planar face, and has a constant thickness. However, the shape of the front wall may also vary if desired, for example to change the cross-sectional areas 452, 454.
  • the rear wall of the device is attached to a mounting piece 490, which contains holes 492 for attaching the perfusion device to a surface for operation.
  • the fluid mixture containing biological cells and smaller molecules enters the acoustic chamber 450 through the inlet port 410.
  • gravity acts to drag the biological cells downwards towards the outlet port 430.
  • a passive settling process occurs in the acoustic chamber, creating a fluid with a relatively high concentration of biological cells at the bottom end 416 of the device, and a fluid with a relatively lower concentration of biological cells at the top end 418 of the device.
  • the vast majority of incoming fluid, and thereby, the large majority of the cell population never passes through the acoustic standing wave(s).
  • the fluid with the high concentration of biological cells is pumped back to the bioreactor, and the fluid with the relatively low concentration of biological cells (and also containing desired biomolecules) is pumped out and collected though the collection port(s) 470, 472.
  • the acoustic standing wave(s) of the device act to prevent significant numbers of biological cells from exiting through the collection port(s) 470, 472.
  • the flow rate through the collection or harvest flow path 453 is, in various embodiments, at least one order of magnitude smaller than the flow rate through the inlet flow path 451.
  • the flow rate of the fluid mixture entering the device through the inlet port is about 1 liter per minute (L/min) and the flow rate of the fluid depleted in cells exiting the device through the collection port(s) is about 10 milliliters per minute (mL/min).
  • bioreactors having a size of 2 liters to 10 liters have been tested with solutions containing up to 10% yeast and up to 50 million cells/mL.
  • the flow rate through the inlet port has been from about 0.75 L/min to about 3 L/min, with the flow rate through the collection flow path (i.e. all collection ports together) being about 1 mL/min to about 30 mL/min. A 95% cell recovery rate has been achieved.
  • the acoustic perfusion devices of the present disclosure can filter very high cell densities, around 100 million cells per mL and possibly in the range of about 20 million to about 120 million cells per ml_, whereas other filtering technologies such as ATF may be limited to being able to filter at densities less than 80 million cells per ml_.
  • the acoustic standing wave(s) can also be tuned to allow passage of cells if desired, as well as allow the passage of fines / debris. This tuning for material passage permits the acoustic standing wave(s) to perform a cleaning operation for the bioreactor. Continuous, steady-state operation is possible without pressure fluctuations, and the product stream does not accumulate in the bioreactor or the filtering device.
  • the acoustic perfusion device can be made of appropriate materials known in the art. Such materials include high density polyethylene (HDPE), other plastics, and potentially metals and glasses. It has been found very convenient for the device to be transparent, so that fluid flow and ultrasonic transducer operation can be visually confirmed.
  • HDPE high density polyethylene
  • Figure 5 shows another embodiment of an acoustic perfusion device 500.
  • This embodiment is very similar to the device 400 depicted in Figure 4.
  • the main difference is that the acoustic perfusion device 500 of Figure 5 has a first ultrasonic transducer 460 on one sidewall of the device and a second ultrasonic transducer 562 on an opposite sidewall 440 thereof in the collection zone 456.
  • the two transducers 460, 562 are located on opposite sides of the collection flow path 453.
  • the reflector 580 is located within the collection zone 456 between the first and second ultrasonic transducers 460, 562.
  • the transducers are oriented so that the reflector 580 and first and second ultrasonic transducers 460, 562 create multidimensional standing wave(s) in the fluid cell 450 as described above, or put another way the transducers are facing each other. Also illustrated is the outflow pump 592 attached to the outlet port 430 of the device, which is used to control the flow rate of the fluid mixture flowing through the device. Not illustrated here is the pump attached to the collection ports (not visible) of the filtering device 500.
  • FIG. 6 a processing system is shown including an associated bioreactor 610 and an acoustic perfusion device 630 of the present disclosure.
  • the system is set up for use as a perfusion bioreactor.
  • the bioreactor 610 includes a reaction vessel 620 having a feed inlet 622, an outlet 624, and a recycle inlet 626. Fresh media is added into the feed inlet 622 by an addition pipe 650.
  • Some reactors will also include an outlet or bleed port (not shown here) to remove or "bleed" cells in order to maintain a constant cell density within a reactor.
  • the contents of the reaction vessel (reference numeral 605) are mixed with an agitator 625.
  • the desired product (e.g., recombinant proteins) is continuously produced by cells located within the vessel 620, and are present in the media of the bioreactor.
  • the product and the cells in the perfusion bioreactor are drawn from the reaction vessel through pipe 652, and enter the acoustic perfusion device 630 through inlet port 632. Therein, a portion of the desired product is separated from the cells.
  • the desired product can be drawn off through a first collection port 634 (which is a product recovery port) and pipe 654 into a containment vessel 640, or in the case of a truly continuous production system, some other downstream purification process.
  • the cells are returned to the perfusion bioreactor after separation, passing from outlet port 636 (which is a fluid recycle port) of the acoustic perfusion device through pipe 656 to recycle inlet 626 of the reaction vessel, which form a recycle path.
  • outlet port 636 which is a fluid recycle port
  • the multi-dimensional standing wave(s) of the acoustic perfusion device are used to create a separation barrier between the fluid cell of the device and the collection port, so that a highly reduced number of biological cells are collected in collection port 634.
  • Figure 7 and Figure 8 are views of another exemplary embodiment of an acoustic perfusion device.
  • Figure 7 is a front cross-sectional view
  • Figure 8 is an exterior perspective view.
  • this embodiment is specifically designed such that it can be fabricated with clean machining techniques, using Class VI materials (medical device grade HDPE, for example), or even as single or welded injection molded part.
  • Class VI materials medical device grade HDPE, for example
  • this embodiment is an example of a single-use device, which is gamma- stable. The devices are flushed to remove bioburden and then gamma-irradiated (generally from 25-40 kGy) to sterilize any potential contamination that could destroy a healthy cell culture, such as that present in a perfusion bioreactor.
  • the inlet port 710 and the collection port 770 are both located at the top end 718 of the device, or on the top wall 776 of the device.
  • the outlet port 730 is located at a bottom end 716 of the device.
  • the inlet port 710 and the outlet port 730 are both on a first side 712 of the device.
  • the inlet flow path 751 is in the form of a channel 755 that runs from the inlet port downwards towards the bottom end and past the outlet port, the channel being separated from the acoustic chamber 750 (here, the separation occurring by an internal wall 756). Fluid will flow downwards in the channel, then rise upwards into the acoustic chamber 750.
  • the bottom wall 720 of the acoustic chamber is a sloped planar surface that slopes down towards the outlet port 730.
  • the location of the ultrasonic transducers 760 are shown here as two squares, between the top end and the bottom end of the device.
  • the collection flow path 753 is located above the transducers.
  • the device 700 is shown as being formed within a three-dimensional rectangular housing 706. It can be seen that the outlet port 730 at the bottom end 716 of the device is located on a front wall 775. Again, the collection port 770 and the inlet port 710 are located on a top wall 776. A viewing window 708 made of a transparent material is present in the front wall. Through that viewing window, it can be seen that the ultrasonic transducers are mounted in the rear wall 778 of the device housing. The viewing window acts as a reflector to generate the multidimensional acoustic standing waves.
  • Figure 9 and Figure 10 are views of yet another exemplary embodiment of an acoustic perfusion device.
  • Figure 9 is a front cross-sectional view
  • Figure 10 is a perspective view.
  • FIG. 9 in this device 900, there is an inlet port 910 present on a front side 975 of the device along the first side 912 of the device.
  • An outlet port 930 (best seen in Figure 10) is located directly opposite and at the same height as the inlet port 910, and is also located on first side 912.
  • there is a main fluid stream that flows almost directly from the inlet port 910 to the outlet port 930, and the inlet flow path 951 diverts a small side flow into the acoustic chamber 950 from the first side 912 of the device.
  • the collection port 970 is located at the top end 918 of the device, or on the top wall 976 of the device.
  • a secondary outlet port 980 is located on the first side 912 of the device as well, extending from first side wall 979, and located below the inlet port 910, and can act as a bleed port.
  • the bottom wall 920 of the acoustic chamber is shaped in a pyramid-like fashion to taper downwards to a vertex.
  • a drain line 981 runs from the bottom of the acoustic chamber 950 to the secondary outlet port 980. It is contemplated that here, the secondary outlet port can be used to capture a small flow of highly concentrated cells, which can either be discarded (cell bleed) or can also be returned back to the bioreactor.
  • the front wall 975 of the device has a rectangular space 960
  • the rear wall 978 of the device has a rectangular space 962. It is contemplated that one transducer and one reflector can be placed in these two rectangular spaces 960/962 in either orientation, or that two transducers could be placed in the two rectangular spaces.
  • the inlet port 910 and outlet port 930 are both visible in this view.
  • the inlet port 910 is located on the front side of the device, and the outlet port 930 is located on the rear side of the device (though this arrangement could be reversed if desired).
  • the clarification flow path 953 is located above the transducers.
  • a mounting piece similar to that in Figure 4 could be attached to the second side 914 of the device.
  • Figures 43-45 are views of yet another exemplary embodiment of an acoustic perfusion device.
  • Figure 43 is a perspective view
  • Figure 10 is a picture showing a front view
  • Figure 45 is a side view.
  • Figure 46A/B and Figure 46C/D are schematic front views of possible interior layouts of the device.
  • Figure 46A and Figure 46B are identical, and are used because of the large number of reference numerals.
  • Figure 46C and Figure 46D are also identical
  • the inlet port 4310 and the outlet port 4330 are both located at the bottom end 4316 of the device, and the collection port 4370 is located at the top end 4318 of the device.
  • the inlet port 4310 is located on a first side 4312 of the device, and the outlet port 4330 is located on a second side 4314 of the device.
  • the outlet port 4330 is attached to a pump 4305, which creates flow through the device 4300.
  • a viewing window 4308 is present on the front wall 4375 of the device.
  • the front wall 4375, top wall 4376, rear wall 4378, and first side wall 4379 are part of the housing 4306 that surrounds the interior of the device.
  • the ultrasonic transducer 4360 is located on the rear wall 4378 at the top end 4318 of the device.
  • the viewing window 4308 acts as a reflector to generate the multi-dimensional acoustic standing waves.
  • a recirculation pipe 4340 connects the inlet port 4310 directly to the outlet port 4330, and forms a recirculation flow path (arrow 4356) through which cell culture media containing cells and other materials can be continuously recirculated through the perfusion device without entering the acoustic chamber 4350.
  • the recirculation pipe 4340 and the recirculation flow path 4356 are located below the acoustic chamber 4350.
  • An inflow passageway 4380 and an outflow passageway 4390 connect the acoustic chamber 4350 to the recirculation pipe 4340, and split off a portion of the flow of cell culture media from the recirculation pipe into the acoustic chamber.
  • Arrow 4351 indicates the inlet flow path
  • arrow 4355 indicates the outlet flow path.
  • FIG. 46A and Figure 46C are front views showing two different internal structures that result in different flow profiles. In these two figures, the inlet port 4310 is on the right, and the outlet port 4330 is on the left.
  • the acoustic chamber 4350 is shown, with the ultrasonic transducer 4360 shown in dashed line.
  • the acoustic chamber 4350 includes a first side wall 4362 and a second side wall 4364.
  • the inflow passageway 4380 also has a first wall 4381 and a second wall 4382, with the first wall 4381 extending beyond the first side wall 4362, or closer to the inlet port 4310.
  • the bottom cross-sectional area of the inflow passageway (adjacent the recirculation pipe 4340) is indicated by reference numeral 4384
  • the top cross-sectional area of the inflow passageway (adjacent the acoustic chamber 4350) is indicated by reference numeral 4383.
  • the top cross-sectional area of the inflow passageway is greater than the bottom cross-sectional area of the inflow passageway.
  • the outflow passageway 4390 also has a first wall 4391 and a second wall 4392. The first wall 4391 and the second wall 4392 taper towards each other from the acoustic chamber 4350 to the recirculation pipe 4340.
  • the bottom cross-sectional area of the outflow passageway (adjacent the recirculation pipe 4340) is indicated by reference numeral 4394
  • the top cross-sectional area of the outflow passageway (adjacent the acoustic chamber 4350) is indicated by reference numeral 4393.
  • the top cross-sectional area of the outflow passageway is greater than the bottom cross-sectional area of the outflow passageway.
  • top cross-sectional area 4393 of the outflow passageway is greater than the top cross-sectional area 4383 of the outflow passageway.
  • the bottom cross-sectional area 4394 of the outflow passageway is also less than the bottom cross- sectional area 4384 of the outflow passageway. Desirably, this arrangement promotes the direction for cells and other larger materials to enter the acoustic chamber 4350, and maximizes their opportunity to exit the acoustic chamber in the same direction as the main recirculation flow.
  • first wall 4381 of the inflow passageway 4380 is essentially in-line with the first side wall 4362.
  • top cross-sectional area 4383 of the inflow passageway is greater than the bottom cross-sectional area 4384of the inflow passageway.
  • the first wall 4391 of the outflow passageway 4390 tapers downwards, and then becomes vertical.
  • the second wall 4392 tapers inwards from the second side wall 4364 to the recirculation pipe 4340.
  • the top cross- sectional area 4393 of the outflow passageway is greater than the bottom cross- sectional area 4394 of the outflow passageway.
  • the top cross-sectional area 4393 of the outflow passageway is still greater than the top cross-sectional area
  • the bottom cross-sectional area 4394 of the outflow passageway can be about equal to or less than the bottom cross-sectional area 4384 of the outflow passageway.
  • Figures 47-49 are views of yet another exemplary embodiment of an acoustic perfusion device.
  • Figure 47 is a perspective view
  • Figure 48 is a side view
  • Figure 49 is a front schematic view of the interior layout of the device.
  • the inlet port 4710 and the outlet port 4730 are both located at the bottom end 4716 of the device, and the collection port 4770 is located at the top end 4718 of the device.
  • the inlet port 4710 is located on the front wall 4775 of the device, and the outlet port 4730 is located on the rear wall 4778 of the device.
  • the outlet port 4730 is attached to a pump 4705, which creates flow through the device 4700.
  • a viewing window 4708 is present on the front wall 4775 of the device.
  • the front wall 4775, top wall 4776, and rear wall 4778 are part of the housing 4706 that surrounds the interior of the device.
  • the ultrasonic transducer 4760 is located on the rear wall 4778 at the top end 4718 of the device.
  • the viewing window 4708 acts as a reflector to generate the multi-dimensional acoustic standing waves.
  • a recirculation pipe 4740 connects the inlet port 4710 directly to the outlet port 4730, and forms a recirculation flow path (arrow 4756) through which cell culture media containing cells and other materials can be continuously recirculated through the perfusion device without entering the acoustic chamber 4750.
  • the recirculation pipe 4740 and the recirculation flow path 4756 are located below the acoustic chamber 4750.
  • FIG. 4772 This embodiment differs from that of Figure 43 in that a single passageway 4772 connects the acoustic chamber 4750 to the recirculation pipe 4740, rather than the two separate passageways (4380, 4390) of Figure 43.
  • arrow 4751 indicates the inlet flow path
  • arrow 4755 indicates the outlet flow path, both traveling through the single passageway. This flow still results in a secondary recirculating flow that is tangential to the acoustic interface, and allows for constant recirculation of cells beneath this acoustic interface, traveling in the same net direction as the recirculation flow path 4756.
  • FIG 11 is a cross-sectional diagram of a conventional ultrasonic transducer.
  • This transducer has a wear plate 50 at a bottom end, epoxy layer 52, ceramic piezoelectric element 54 (made of, e.g. Lead Zirconate Titanate (PZT)), an epoxy layer 56, and a backing layer 58.
  • PZT Lead Zirconate Titanate
  • the epoxy layer 56 attaches backing layer 58 to the piezoelectric element 54.
  • the entire assembly is contained in a housing 60 which may be made out of, for example, aluminum.
  • the housing is used as the ground electrode.
  • An electrical adapter 62 provides connection for wires to pass through the housing and connect to leads (not shown) which attach to the piezoelectric element 54.
  • backing layers are designed to add damping and to create a broadband transducer with uniform displacement across a wide range of frequency and are designed to suppress excitation of particular vibrational eigen-modes of the piezoelectric element.
  • Wear plates are usually designed as impedance transformers to better match the characteristic impedance of the medium into which the transducer radiates.
  • FIG 12 is a cross-sectional view of an ultrasonic transducer 81 according to an example of the present disclosure, which is used in the acoustic filtering device of the present disclosure.
  • Transducer 81 is shaped as a disc or a plate, and has an aluminum housing 82.
  • the aluminum housing has a top end and a bottom end.
  • the transducer housing may also be composed of plastics, such as medical grade HDPE or other metals.
  • the piezoelectric element is a mass of perovskite ceramic, each consisting of a small, tetravalent metal ion, usually titanium or zirconium, in a lattice of larger, divalent metal ions, usually lead or barium, and O 2" ions.
  • a PZT (lead zirconate titanate) piezoelectric element 86 defines the bottom end of the transducer, and is exposed from the exterior of the bottom end of the housing.
  • the piezoelectric element is supported on its perimeter by a small elastic layer 98, e.g. epoxy, silicone or similar material, located between the piezoelectric element and the housing. Put another way, no wear plate or backing material is present.
  • a layer of plastic or other material separating the piezoelectric element from the fluid in which the acoustic standing wave is being generated.
  • the piezoelectric element / crystal has an exterior surface (which is exposed) and an interior surface as well.
  • the piezoelectric element / crystal is an irregular polygon, and in further embodiments is an asymmetrical irregular polygon.
  • Screws 88 attach an aluminum top plate 82a of the housing to the body 82b of the housing via threads.
  • the top plate includes a connector 84 for powering the transducer.
  • the top surface of the PZT piezoelectric element 86 is connected to a positive electrode 90 and a negative electrode 92, which are separated by an insulating material 94.
  • the electrodes can be made from any conductive material, such as silver or nickel. Electrical power is provided to the PZT piezoelectric element 86 through the electrodes on the piezoelectric element. Note that the piezoelectric element 86 has no backing layer or epoxy layer.
  • a minimal backing 58 (on the interior surface) and/or wear plate 50 (on the exterior surface) may be provided in some embodiments, as seen in Figure 13.
  • the transducer design can affect performance of the system.
  • a typical transducer is a layered structure with the ceramic piezoelectric element bonded to a backing layer and a wear plate. Because the transducer is loaded with the high mechanical impedance presented by the standing wave, the traditional design guidelines for wear plates, e.g., half wavelength thickness for standing wave applications or quarter wavelength thickness for radiation applications, and manufacturing methods may not be appropriate. Rather, in one embodiment of the present disclosure the transducers, there is no wear plate or backing, allowing the piezoelectric element to vibrate in one of its eigenmodes with a high Q-factor, or in a combination of several eigenmodes. The vibrating ceramic piezoelectric element/disk is directly exposed to the fluid flowing through the fluid cell.
  • Removing the backing also permits the ceramic piezoelectric element to vibrate at higher order modes of vibration with little damping (e.g. higher order modal displacement).
  • the piezoelectric element vibrates with a more uniform displacement, like a piston.
  • Removing the backing allows the piezoelectric element to vibrate in a non-uniform displacement mode.
  • the higher order the mode shape of the piezoelectric element the more nodal lines the piezoelectric element has.
  • the higher order modal displacement of the piezoelectric element creates more trapping lines, although the correlation of trapping line to node is not necessarily one to one, and driving the piezoelectric element at a higher frequency will not necessarily produce more trapping lines.
  • the piezoelectric element may have a backing that minimally affects the Q-factor of the piezoelectric element (e.g. less than 5%).
  • the backing may be made of a substantially acoustically transparent material such as balsa wood, foam, or cork which allows the piezoelectric element to vibrate in a higher order mode shape and maintains a high Q-factor while still providing some mechanical support for the piezoelectric element.
  • the backing layer may be a solid, or may be a lattice having holes through the layer, such that the lattice follows the nodes of the vibrating piezoelectric element in a particular higher order vibration mode, providing support at node locations while allowing the rest of the piezoelectric element to vibrate freely.
  • the goal of the lattice work or acoustically transparent material is to provide support without lowering the Q-factor of the piezoelectric element or interfering with the excitation of a particular mode shape.
  • the piezoelectric element in direct contact with the fluid also contributes to the high Q-factor by avoiding the dampening and energy absorption effects of the epoxy layer and the wear plate.
  • Other embodiments of the transducer(s) may have wear plates or a wear surface to prevent the PZT, which contains lead, from contacting the host fluid.
  • This additional layer may be desirable in, for example, biological applications such as separating blood, biopharmaceutical perfusion, or fed- batch filtration of mammalian cells. Such applications might use a wear layer such as chrome, electrolytic nickel, or electroless nickel. Chemical vapor deposition could also be used to apply a layer of poly(p-xylylene) (e.g. Parylene) or other polymer.
  • Organic and biocompatible coatings such as silicone or polyurethane are also usable as a wear surface.
  • Thin films such as a PEEK film, can also be used as a cover of the transducer surface exposed to the fluid with the advantage of being a biocompatible material.
  • the PEEK film is adhered to the face of the piezomaterial using pressure sensitive adhesive (PSA).
  • PSA pressure sensitive adhesive
  • Other films can be used as well.
  • the ultrasonic transducer has a nominal 2 MHz resonance frequency.
  • Each transducer can consume about 28 W of power for droplet trapping at a flow rate of 3 GPM. This power consumption translates to an energy cost of 0.25 kW hr/ m 3 This cost is an indication of the very low cost of energy of this technology.
  • each transducer is powered and controlled by its own amplifier.
  • the ultrasonic transducer uses a square piezoelectric element, for example with 1"x1 " dimensions.
  • the ultrasonic transducer can use a rectangular piezoelectric element, for example with 1 "x2.5" dimensions.
  • Power dissipation per transducer was 10 W per 1 "x1 " transducer cross-sectional area and per inch of acoustic standing wave span in order to get sufficient acoustic trapping forces.
  • each 1"x1 " square transducer consumes 40 W.
  • the larger 1 "x2.5" rectangular transducer uses 100W in an intermediate scale system.
  • the array of three 1 "x1 " square transducers would consume a total of 120 W and the array of two 1 "x2.5” transducers would consume about 200 W.
  • Arrays of closely spaced transducers represent alternate potential embodiments of the technology. Transducer size, shape, number, and location can be varied as desired to generate desired multi-dimensional acoustic standing wave patterns.
  • the size, shape, and thickness of the transducer can determine the transducer displacement at different frequencies of excitation. Transducer displacement with different frequencies may affect separation efficiency. Typically, the transducer is operated at frequencies near the thickness resonance frequency (half wavelength). Gradients in transducer displacement typically result in more trapping locations for the cells/biomolecules. Higher order modal displacements can generate three-dimensional acoustic standing waves with strong gradients in the acoustic field in all directions, thereby creating strong acoustic radiation forces in all directions, which forces may, for example, be equal in magnitude, leading to multiple trapping lines, where the number of trapping lines correlate with the particular mode shape of the transducer.
  • Figure 14 shows the measured electrical impedance amplitude of a square transducer as a function of frequency in the vicinity of the 2.2 MHz transducer resonance.
  • the minima in the transducer electrical impedance correspond to acoustic resonances of the water column and represent potential frequencies for operation. Additional resonances exist at other frequencies where multi-dimensional standing waves are excited.
  • Numerical modeling has indicated that the transducer displacement profile varies significantly at these acoustic resonance frequencies, and thereby directly affects the acoustic standing wave and resulting trapping force. Since the transducer operates near its thickness resonance, the displacements of the electrode surfaces are essentially out of phase. The typical displacement of the transducer electrodes may not be uniform and varies depending on frequency of excitation.
  • the displacement has a single maximum in the middle of the electrode and minima near the transducer edges.
  • the transducer profile has multiple maxima leading to multiple trapped lines of oil droplets. Higher order transducer displacement patterns result in higher trapping forces and multiple stable trapping lines for the captured oil droplets.
  • the trapping lines of oil droplets were observed and characterized.
  • the characterization involved the observation and pattern of the number of trapping lines across the fluid channel, as shown in Figure 15, for seven of the ten resonance frequencies identified in Figure 14.
  • Different displacement profiles of the transducer can produce different (more) trapping lines in the standing waves, with more gradients in displacement profile generally creating higher trapping forces and more trapping lines.
  • Different displacement profiles of the transducer can produce different (more) trapping lines in the standing waves, with more gradients in displacement profile generally creating higher trapping forces and more trapping lines. It is noted that although the different trapping line profiles shown in Figure 15 were obtained at the frequencies shown in Figure 14, these trapping line profiles can also be obtained at different frequencies.
  • Figure 15 shows the different crystal vibration modes possible by driving the crystal to vibrate at different fundamental frequencies of vibration.
  • the 3D mode of vibration of the crystal is carried by the acoustic standing wave across the fluid in the chamber all the way to the reflector and back.
  • the resulting multi-dimensional standing wave can be thought of as containing two components.
  • the first component is a planar out-of-plane motion component (uniform displacement across crystal surface) of the crystal that generates a standing wave
  • the second component is a displacement amplitude variation with peaks and valleys occurring in lateral directions across the crystal surface.
  • Three-dimensional force gradients are generated by the standing wave. These three-dimensional force gradients result in lateral radiation forces that stop and trap the particles with respect to the flow by overcoming the viscous drag force.
  • particle separation and gravity-driven collection depends on generating a multi-dimensional standing wave that can overcome the particle drag force as the mixture flows through the acoustic standing wave.
  • Multiple particle clusters are formed along trapping lines in the axial direction of the standing wave, as presented schematically in Figure 15.
  • Figure 16 is a numerical model showing a pressure field that matches the 9 trapping line pattern.
  • the numerical model is a two-dimensional model; and therefore three trapping lines are observed. Two more sets of three trapping lines exist in the third dimension perpendicular to the plane of the page.
  • the lateral force of the acoustic radiation force generated by the transducer can be increased by driving the transducer in higher order mode shapes, as opposed to a form of vibration where the crystal effectively moves as a piston having a uniform displacement.
  • the acoustic pressure is proportional to the driving voltage of the transducer.
  • the electrical power is proportional to the square of the voltage.
  • the transducer is typically a thin piezoelectric plate, with electric field in the z-axis and primary displacement in the z-axis.
  • the transducer is typically coupled on one side by air (i.e., the air gap within the transducer) and on the other side by the fluid mixture of the cell culture media.
  • the types of waves generated in the plate are known as composite waves.
  • a subset of composite waves in the piezoelectric plate is similar to leaky symmetric (also referred to as compressional or extensional) Lamb waves.
  • the piezoelectric nature of the plate typically results in the excitation of symmetric Lamb waves.
  • the waves are leaky because they radiate into the water layer, which result in the generation of the acoustic standing waves in the water layer.
  • Lamb waves exist in thin plates of infinite extent with stress free conditions on its surfaces. Because the transducers of this embodiment are finite in nature, the actual modal displacements are more complicated.
  • Figure 17 shows the typical variation of the in-plane displacement (x- displacement) and out-of-plane displacement (y-displacement) across the thickness of the plate, the in-plane displacement being an even function across the thickness of the plate and the out-of-plane displacement being an odd function.
  • the displacement components vary across the width and length of the plate.
  • a (m,n) mode is a displacement mode of the transducer in which there are m undulations in transducer displacement in the width direction and n undulations in the length direction, and with the thickness variation as described in Figure 17.
  • the maximum number of m and n is a function of the dimension of the crystal and the frequency of excitation. Additional three-dimensional modes exist that are not of the form (m,n).
  • the transducers are driven so that the piezoelectric element vibrates in higher order modes of the general formula (m, n), where m and n are independently 1 or greater.
  • the transducers will vibrate in higher order modes than (2,2).
  • Higher order modes will produce more nodes and antinodes, result in three-dimensional standing waves in the water layer, characterized by strong gradients in the acoustic field in all directions, not only in the direction of the standing waves, but also in the lateral directions.
  • the acoustic gradients result in stronger trapping forces in the lateral direction.
  • the transducer can be driven by a signal, such as a voltage signal, a current signal, a magnetic signal, an electromagnetic signal, a capacitive signal, or any other type of signal to which the transducer is responsive to create a multi-dimensional acoustic standing wave.
  • the voltage signal driving the transducer can have a sinusoidal, square, sawtooth, pulsed, or triangle waveform; and have a frequency of 500 kHz to 10 MHz.
  • the voltage signal can be driven with pulse width modulation, which produces any desired waveform.
  • the voltage signal can also have amplitude or frequency modulation start/stop capability to eliminate streaming.
  • the transducers are used to create a pressure field that generates acoustic radiation forces of the same order of magnitude both orthogonal to the standing wave direction and in the standing wave direction.
  • forces are roughly the same order of magnitude, particles of size 0.1 microns to 300 microns will be moved more effectively towards "trapping lines", so that the particles will not pass through the pressure field and continue to exit through the collection ports of the filtering device. Instead, the particles will remain within the acoustic chamber to be recycled back to the bioreactor.
  • the parts of the system i.e., the bioreactor, acoustic filtering device, tubing fluidly connecting the same, etc.
  • the transducers may also be driven to create rapid pressure changes to prevent or clear blockages due to agglomeration of CHO cells.
  • the frequency of the transducers may also be varied to obtain optimal effectiveness for a given power.
  • Figure 18 shows an experimental setup for an acoustic perfusion device as described in detail above.
  • This acoustic perfusion device is very similar to that illustrated in Figure 5, except the bottom wall is not curved, but rather runs horizontally from the first end and then angles directly to the outlet port. Tubes are connected to the inlet port, outlet port, and the two collection ports. A pump is also visibly fluidly connected to the outlet port.
  • Figure 19 is a picture of another acoustic perfusion device of the present disclosure, similar to the embodiment shown in Figure 5, having two ultrasonic transducers and a concave bottom wall leading from the inlet port to the outlet port at the bottom end of the device. A cell containing fluid mixture is also present in the device.
  • acoustic standing waves are created in the collection zone between the reflector and first and second transducers as described above. The acoustic field generated thereby is indicated by waves and reference numeral 1664.
  • the perfusion flow rates with the acoustic filtering device were from about 2 mL/min to about 10 mL/min, or the flow rates were about 1 WD to about 5 WD for a 2.7L working volume bioreactor.
  • the WD refers to the "vessel volume per day", or how many times the volume of the bioreactor vessel is cycled through the acoustic filtering device in one day.
  • the perfusion flow rate (Qp) was collected through the perfusion ports.
  • the feed flow rates (Qf) were from about 40 mL/min to about 200 mL/min.
  • the feed solution had a starting CHO cell density of 50x10 6 cells/mL.
  • the reactor size was 2.7L and the feed volume of the host fluid was 1 .5L.
  • T1 -T7 a series of seven tests (T1 -T7) were performed to study the effect of varying the WD and flow split in a 2.7L volume reactor. The parameters for the tests are shown in Table 1 below.
  • the results further included a perfusate turbidity reduction of 90-94% compared to the feed, as shown in Figure 21.
  • This figure shows the turbidity of the feed, the recirculated fluid (Qc), and the perfusate (Qp).
  • the feed entered the inlet port, the recirculated fluid exited the outlet port and was recirculated, and the perfusate exited the perfusion port of the acoustic filtering device. It is noted that the turbidity measurements for tests T1 and T2 resulted in a hardware error, and their results are not displayed. The results of tests T3-T7 are displayed, which equated to a 6-10% turbidity in the perfusion stream relative to the feed stream, regardless of flow rate.
  • Figure 22 was produced by a Beckman Coulter Cell Viability Analyzer and revealed a cell viability for each flow rate that was within the error of instrument (i.e., ⁇ 6%), with the control ranging from 79-84% over all tests.
  • CHO Line A Further testing was performed using a solution designated "CHO Line A".
  • the solution had a starting cell density of 50x10 6 cells/mL, a turbidity of 2,400 NTU, and cell viability of roughly 80%.
  • the solution was separated using a device of the present disclosure in a system having a reactor size of 2.7L.
  • the volume of the feed fluid was between 1.5L and 2.0L.
  • the perfused flow rates were from 2 mL/min to 10 mL/min, or from 1 to 5 WD.
  • a series of six tests were performed to study the effect of varying the WD and flow split on acoustic filtration performance for the 2.7L volume reactor. The parameters for the tests are shown in Table 2 below.
  • Figure 23 shows the measured total cell density of feed flow, recirculation flow, and perfused flow.
  • the bioreactor cell retention for the tests shows an approximately 90% perfusion efficiency.
  • Figure 24 shows the measured cell viability for the tests, revealing no significant change in viability across the tests.
  • Figure 25 shows the measured total cell density of feed, recirculation, and perfusion flows.
  • the bioreactor cell retention for the tests shows a perfusion efficiency greater than 90%.
  • the results further evidenced an approximately 3-5% greater efficiency when using two transducers rather than a single transducer.
  • Figure 26 shows the measured cell viability for the tests, revealing no significant change in viability across the tests. Practically speaking, operating at low WD offers a number of advantages, such as media cost reduction.
  • Figure 27 shows another experimental setup for an acoustic perfusion device similar to that illustrated in Figure 8. Tubes are connected to the inlet port, outlet port, and the collection port.
  • the device was tested at a transducer voltage of 40V peak to peak, a perfused flow rate of 15-30 mL/min, and a recirculation flow rate of 2 L/min. Samples were taken every 45-60 minutes, and the cell retention rate was determined. Figure 28 shows the results.
  • the y-axis is the retention, stated in terms of percentage (calculated by comparing the output cell count with the input, or bioreactor/culture cell count).
  • the x-axis is both the applied DC voltage (in V) and the perfused, or harvest, flow rate (in mL/min); it is merely coincidental that the range of numeric values for V and mL/min are the same.
  • Figure 33 is a composite picture showing the device in a startup or cell settling mode (left) and in a steady state cell retention mode (right).
  • Figure 29A is a microscope image (from a Vi- Cell cell counter) of the feed suspension, here a viable cell culture population with approximately 56 million cells/mL. Several large, round, healthy cells can be observed.
  • Figure 29B is a histogram showing the distribution of cell diameter in the population. The diameter distribution is strongly bi-modal, around values of about 1 1 microns and about 23 microns. These two modes correspond roughly with the smaller debris and non-viable cells, and the larger viable cells. It should be noted that this sample is from a particularly "dirty" cell population. In general, a production cell line would be far cleaner, and the peak at approximately 1 1 microns would be much smaller, or even non-existent.
  • Figure 30A is another microscope image (from a Vi-Cell cell counter), this time of the flow harvested from the acoustic perfusion device. In this image, very few bright, large cells are observed, in contrast to Figure 29A. Rather, the image is filled with more smaller, darker particles, or debris.
  • the experimental conditions in this case were a perfused rate of 4 mL/min and a recirculation rate of 2L/min with a DC input voltage of 30V.
  • Figure 30B shows the distribution of diameters in the perfusate. Looking at Figure 30B, the particle distribution is now unimodal, with the peak of approximately 9 microns. This distribution indicates that the larger, viable cells have been trapped and retained, or otherwise largely prevented from exiting in the perfusate. Smaller cells are passing through, together with cell debris, fines, and fragments, from submicron to micron sized.
  • FIG. 31 shows the velocity distributions within the device after 500 seconds. The units are in meters/second (m/s). As expected, the highest velocities are found in the channel leading downwards from the inlet port to the outlet port. The velocity is near zero in the fluid cell and out through the collection port. This velocity profile is important for two reasons: the acoustic field is more effective in a flow with a lower, more uniform velocity, and because the cells used in bio-manufacturing are sensitive to flow, and the induced shear rate.
  • Figure 32 is a diagram illustrating several aspects of this embodiment. Fluid flows into the device through the inlet port 710 (arrow 780) and into the acoustic chamber 790.
  • the volume of fluid 750 below the acoustic chamber contains the tangential flow path, indicated by arrow 782. Fluid with a relatively high amount of viable cells will exit through the outlet port 730, as indicated by arrow 781.
  • the acoustic interface effect / region created by the standing waves is marked with reference numeral 783, and is upstream of the acoustic standing wave field 784.
  • the acoustic interface roughly coincides with an x-y plane in this diagram.
  • This interface effect separates large cells from smaller cell fragments, particulate debris, desired biomolecules, etc., which can pass through the interface 783 and the acoustic standing wave field 784.
  • the cell aggregates that arise within the acoustic standing wave field 784 during the first mode of operation can be described as being aligned in the y-z plane.
  • the separation caused by the interface effect occurs at the interface region 783 as any large cells are held back by the "interface” or "barrier” effect.
  • the harvest flow stream 785 containing the smaller fragments, particulate debris, desired biomolecules, etc. then exits through harvest port 770.
  • Figure 61 shows a device 6100 that is substantially similar to the device 700 of Figure 7 and Figure 32. The same numbering is used in Figure 61. The main difference between the device illustrated in Figure 32 and that illustrated in Figure 61 is the flow of particles near transducers 760, which is illustrated with arrow 6153, which runs down past the transducers 760 and down to acoustic interface effect / region 783.
  • This flow pattern near transducers 760 occurs because the particles in Figure 61 are too small or have an acoustic contrast factor that is insufficient to be affected by the acoustic standing wave created by transducers 760 (and the reflector), and so they can reenter the acoustic standing wave. This behavior may also be affected by the buoyancy characteristics of the particles and the fluid flow of the system, and thus the Stokes drag experienced by the particles.
  • Figure 34 shows the geometry of the simulation, utilizing a piezoelectric transducer, steel reflector, aluminum housing, and two fluids: the first fluid being water within the acoustic field, simulating the clarified fluid, and the second fluid being a 15% concentration of CHO cells in water solution outside of the acoustic field, the second fluid having a higher density and higher speed of sound than the water fluid and simulating the bioreactor fluid containing the cells.
  • a coupled multi-physics numerical simulation that included a full piezoelectric simulation of the piezoelectric material, an acoustic simulation of the two fluids, and a linear elastic simulation in the steel and aluminum bodies was performed at various frequencies of excitation.
  • the transducer was driven at a peak voltage of 40 V.
  • Figures 35A-35C show the acoustic pressure in the two fluids and the displacement of the piezoelectric material, the aluminum housing, and the steel reflector of the model at frequencies of operation of 2.218 MHz, 2.2465 MHz, and 2.3055MHz.
  • the lateral radiation force i.e., horizontally in the direction of the fluid flow
  • the structural displacement of the transducer and steel are shown, along with the acoustic pressure in the fluid.
  • Figure 36 shows the lateral radiation force (N) and the lateral radiation force normalized by power (N/W) versus frequency acting on the suspended CHO cells. This graph shows that at the resonance frequencies (i.e., local maxima in power), the average lateral radiation force on the interface is negative, meaning that it is in the negative-x direction. The result is the creation of an acoustic barrier effect or an acoustic interface effect.
  • the acoustic field at the interface between the two fluids exerts a strong lateral force on the suspended particles in a direction opposite to the fluid flow, thereby keeping the larger particles from entering the acoustic field and allowing the first fluid (i.e., fluid containing smaller particles, such as the desired product, and excluding whole cells) to enter the acoustic field, thereby creating an acoustic perfusion cell retention device.
  • the first fluid i.e., fluid containing smaller particles, such as the desired product, and excluding whole cells
  • the clarified fluid can escape and the cells are held back by the radiation force. This force is never positive, meaning that it always holds the cells back at the interface, not allowing them to cross the interface.
  • the multiple peaks in the power curve show the existence of multiple modes of operation including planar resonance modes and multi-dimensional modes of operation, indicating that this type of operation can be generated through utilization of planar and multi-dimensional standing waves alike.
  • planar resonance modes In systems having 1 "x1 " dimensions, there exists a planar resonance about every 30 kHz.
  • the graph shows evidence of additional peaks indicating the existence of the multi-dimensional modes. Per unit power, these modes can be equally or even more effective as the planar resonance modes.
  • the cells that are held back by the acoustic radiation force may then be picked up by the scrubbing motion of the flow field (i.e., the recirculating flow underneath the interface), and be continuously returned to the bioreactor to ensure they receive the nutrition and oxygen to maintain the production of the overall cell culture.
  • Figure 37 and Figure 38 show another experimental setup for an acoustic perfusion device similar to that illustrated in Figure 9. Tubes are connected to the inlet port, outlet port, the collection port, and the secondary outlet port (for a flow concentrated cells). Arrows are included to illustrate fluid flow. Arrows indicate the flow into the inlet port; the flow out of the outlet port; the perfusate flow out the top of the device and the flow of concentrate out the bottom of the device. The flow through the inlet port to the outlet port is the recirculation flowrate. The perfusate flow out the top of the device is the perfused flowrate containing clarified fluid depleted in cells and containing desired product. The flow of concentrate out the bottom of the device is the concentrated cell flow. The concentrated cell flow can be used for a cell bleed operation or if desired, the cells can be returned to the bioreactor.
  • the device was tested at a transducer voltage of 40V peak to peak, a perfused flow rate (out the top) of 1 -10 mL/min, a recirculation flow rate of 0.75-1 L/min, and a concentrate flow rate (out the bottom) of 15 mL/min.
  • the cell retention rate was determined for different perfused flowrates.
  • Figure 39 shows the results.
  • the y-axis is the retention with 1.00 indicating 100% retention.
  • the cell retention efficiency remained above 98% for perfused flow rates up to 7 mL/min, and was just below 90% at 10 mL/min.
  • Figure 50 shows the cell retention (%) versus time. Here, higher values are more desirable, and most values were over 95% at flowrates ranging from 1 .5 mL/min to 8 mL/min.
  • Figure 51 shows the perfusate cell density (million cells/mL) versus time. Here, lower values are more desirable (indicating successful cell separation). As expected, results were better at lower flowrates.
  • FIG. 52 A computational fluid dynamics (CFD) model was made of the device with the internal structure of Figure 46A.
  • Figure 52 shows the velocity distributions within the device after 500 seconds. The units are in meters/second (m/s). It is noted that here, the inlet is from the left-hand side of the figure, and the outlet is on the right-hand side of the figure (flow direction indicated by the arrow). As expected, the highest velocities are found in the inflow passageway into the acoustic chamber. Negative velocities in the outflow passageway indicate flow out of the acoustic chamber. The velocity is near zero in the acoustic chamber, and near the collection port at the top thereof. This velocity profile is desirable for perfusion operation.
  • FIG. 53 shows the velocity distributions within the device at a flow rate of 250 mL/min
  • Figure 54 shows the velocity distributions within the device at a flow rate of 1000 mL/min.
  • the inlet is from the right-hand side of the figure
  • the outlet is on the left-hand side of the figure (flow direction indicated by the arrow).
  • the velocity is near zero in the acoustic chamber, and near the collection port at the top thereof, even at the much higher flow rate of 1000 mL/min. This velocity profile is desirable for perfusion operation.
  • FIG. 53 and Figure 54 Two further CFD models were made of variants of the configurations seen in Figure 53 and Figure 54, which are potential internal structures for the device of Figure 43.
  • the first variant is seen in Figure 55.
  • the rectangle at the top indicates the location of the ultrasonic transducer / multi-dimensional acoustic standing wave.
  • the sides of the acoustic chamber taper evenly down to the outflow passageway.
  • the inflow passageway has an arcuate top into the acoustic chamber.
  • FIG 56 This variant is much taller and narrower compared to Figure 55.
  • the outflow side of the acoustic chamber tapers evenly down to the outflow passageway.
  • the desirable velocity profile is present, being near zero in the area of the multi-dimensional acoustic standing wave, and near the collection port at the top thereof.
  • Figures 52-56 demonstrate how the fluid may be managed through different configurations of the geometry leading from the main recirculation path (through the recirculation pipe) to the acoustic chamber.
  • the main recirculation path to the fluid chamber have the same flow rate.
  • One consequence of these configurations is that the separation velocities will be higher.
  • Figure 57 shows the cell retention (%) versus time. Higher values are more desirable, and most values were over 97% at flowrates ranging from 0.37 mL/min to 1 .5 mL/min.
  • Figure 58 shows the perfusate cell density (million cells/mL) versus time. Here, lower values are more desirable (indicating successful cell separation). As expected, results were better at lower flowrates.
  • FIG. 59 shows the cell retention (%) versus time. Higher values are more desirable. At 2 MHz, the values were close to 100% for flow rates of 1 .5 mL/min to 3 mL/min. At 1 MHz, the values stayed over 90% for flow rates of 1 .5 mL/min to 3 mL/min. The frequency of 2 MHz generally performed better.
  • Figure 60 shows the perfusate cell density (million cells/mL) versus time. Again, results were better for 2 MHz operating frequency.
  • FIG. 10 a device with an internal structure similar to Figure 10 was used to perform acoustic separation of beads and yeast from a host fluid.
  • the device was a 1 inch by 1 inch by 1 inch device using a 1 inch by 1 inch crystal to separate beads from a yeast mixture having a concentration of 1 *10 6 cells/mL.
  • the ultrasonic transducer was operated at 1 MHz with an input voltage of 60 volts, and the beads were Solohill microcarriers in the amount of 7.5 g/L.
  • the mixture was flowed into the device at a flow rate of 75 mL/minute, while the concentrate was recovered at a rate of 5 mL/minute.
  • Figure 62 shows a photograph of the microcarriers being trapped in the acoustic standing wave within the device.
  • Figure 64 shows the viable cell density (leftside y-axis), AWS power (right-side y-axis), and harvest to recirculation ratio (right-side y-axis) over a period of about 28 days.
  • the dark dots represent the bioreactor, while the light dots represent the AWS harvest.
  • the system was operated with AWS beginning on day 7 through the end of the study. From day 7 to day 20, the system was operated at 30% AWS power, before being switched to 10% AWS power from day 20 to the end of the study.
  • the harvest to recirculation ratio was about 15% from day 7 (start of AWS) to day 1 1 , about 30% from day 1 1 to the end of the study.
  • FIG. 65 The cell separation efficiency was dominated by the harvest to recirculation flow ratio, as shown in Figure 65 which compares the AWS power (x-axis) to the harvest to recirculation flow ratio (y-axis).
  • the device was then paired with a 10L bioreactor, and the AWS cell separation efficiency was again examined.
  • Figures 66A- 66C show similar volumetric productivity, improved product transmission, and improved product residence time for AWS versus TFF.
  • Figure 67 shows the cell separation efficiency (right-side y-axis), the harvest VCD (left-side y-axis), and bioreactor VCD (leftside y-axis) over a period of about 14 days.
  • the system had a greater than 90% cell separation at 30% AWS power and a 1 .25% harvest to recirculation ratio.
  • Figure 68A graphically shows the relative abundance after size exclusion chromatography (SEC) of high molecular weight (HMW) species, monomer species, and low molecular weight (LMW) species of a monoclonal antibody (mAb).
  • SEC size exclusion chromatography
  • LMW monomer species
  • LMW low molecular weight
  • mAb monoclonal antibody
  • Figure 68B graphically shows the relative abundance after ion exchange chromatography (IEX) of acidic, main peak, and basic species of a mAb.
  • IEX ion exchange chromatography
  • the darker bars represent the bioreactor, and the lighter bars represent the harvest.
  • Figure 68C shows glycosylation of the protein. The effects are the same for the protein that is from the bioreactor and for the protein that has passed through the acoustic separation device. These results show that acoustics do not affect the protein.
  • FIG. 69A graphically shows the relative abundance after size exclusion chromatography (SEC) of HMW species, monomer species, and LMW species of a monoclonal antibody (mAb).
  • SEC size exclusion chromatography
  • mAb monoclonal antibody
  • TFF tangential flow filtration
  • Figure 69B graphically shows the relative abundance after ion exchange chromatography (IEX) of acidic, main peak, and basic species of a mAb.
  • IEX ion exchange chromatography
  • Figure 70 depicts another device 7000 that can be used for acoustophoresis.
  • Device 7000 includes a first inlet port 7002 along a front wall 7011 of the device near the top end 7001 of the device.
  • a second inlet port (not shown) can be located along a rear wall 7013 of the device opposite the front wall 7011 thereof.
  • a viewing window 7050 made of a transparent material is also present in the front wall 7011. Through the viewing window 7050, it can be seen that an ultrasonic transducer 7020 is also coupled to the rear wall 7013. In this embodiment, the viewing window 7050 acts as a reflector to generate the multi-dimensional acoustic standing wave(s).
  • Both the reflector and the ultrasonic transducer are generally located below the inlet(s), such that the acoustic chamber is positioned below the inlet(s).
  • the first and second inlets are located directly opposite one another in the device.
  • a drain outlet 7006 is located near a bottom end 7003 of the device above the acoustic chamber, and here is located along a first sidewall 7015 of the device.
  • the drain outlet generally serves as the outlet through which the concentrate fluid (retained material prevented from passing through the standing wave) is recovered from the device.
  • a permeate outlet 7007 which generally serves as the outlet through which the permeate (material that passes through the standing wave) is recovered from the device, is located above the acoustic chamber, and as illustrated here is also located along the first sidewall 7015 of the device above the drain outlet 7006.
  • the device 7000 includes a cooling unit 7060 coupled to the rear wall 7013.
  • the cooling unit 7060 includes an independent flow path that is separate from the flow path through the device containing the fluid that is to be exposed to the multidimensional acoustic standing wave.
  • a coolant inlet 7062 is adapted to permit the ingress of a cooling fluid into the cooling unit.
  • a coolant outlet 7064 serves as the outlet through which the coolant and waste heat exit the cooling unit.
  • the coolant inlet is located below the coolant outlet, though this path can be varied as desired.
  • the coolant that flows through the cooling unit can be any appropriate fluid.
  • the coolant can be water, air, alcohol, ethanol, ammonia, or some combination thereof.
  • the coolant can, in certain embodiments, be a liquid, gas, or gel.
  • the coolant can be an electrically non-conductive fluid to prevent electric short-circuits.
  • the cooling unit can be used to cool the ultrasonic transducer, which can be particularly advantageously when the device is to be run continuously with repeated processing and recirculation for an extended period of time (e.g., perfusion).
  • the cooling unit can also be used to cool the host fluid running through the device 7000, if desired.

Landscapes

  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Sustainable Development (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Thermal Sciences (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Mechanical Engineering (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)

Abstract

La présente invention concerne des procédés de séparation de billes et de cellules à partir d'un fluide hôte. Le procédé comprend l'écoulement d'un mélange contenant le fluide hôte, les billes et les cellules à travers un dispositif acoustophorétique comportant un transducteur ultrasonore comprenant un matériau piézoélectrique commandé par un signal de commande afin de créer une onde acoustique stationnaire multidimensionnelle. Un signal de commande est envoyé pour commander l'au moins un transducteur ultrasonore pour créer l'onde acoustique stationnaire multidimensionnelle. Un flux de fluide de recirculation ayant un trajet d'écoulement tangentiel est situé de façon sensiblement tangentielle à l'onde stationnaire et séparé de celle-ci par une région d'interface. Une partie des cellules traverse l'onde stationnaire, et les billes sont maintenues séparées de l'onde stationnaire dans le flux de fluide de recirculation au niveau de la région d'interface. L'invention concerne en outre un dispositif acoustophorétique comportant une entrée de réfrigérant conçue pour permettre l'entrée d'un fluide de refroidissement dans le dispositif pour refroidir le transducteur.
PCT/US2017/015689 2016-01-29 2017-01-30 Dispositifs de perfusion acoustique Ceased WO2017132694A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GB1812196.2A GB2562937B (en) 2016-01-29 2017-01-30 Acoustic perfusion devices
CA3013052A CA3013052A1 (fr) 2016-01-29 2017-01-30 Dispositifs de perfusion acoustique

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201662288500P 2016-01-29 2016-01-29
US62/288,500 2016-01-29
US201662296685P 2016-02-18 2016-02-18
US62/296,685 2016-02-18
US201662307934P 2016-03-14 2016-03-14
US62/307,934 2016-03-14
US15/139,187 US9752113B2 (en) 2012-03-15 2016-04-26 Acoustic perfusion devices
US15/139,187 2016-04-26

Publications (1)

Publication Number Publication Date
WO2017132694A1 true WO2017132694A1 (fr) 2017-08-03

Family

ID=58228539

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2017/015689 Ceased WO2017132694A1 (fr) 2016-01-29 2017-01-30 Dispositifs de perfusion acoustique

Country Status (3)

Country Link
CA (1) CA3013052A1 (fr)
GB (1) GB2562937B (fr)
WO (1) WO2017132694A1 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3642621A1 (fr) * 2017-04-26 2020-04-29 Bart Lipkens Sélection de cellule par affinité en lit expansé
WO2020232370A1 (fr) * 2019-05-15 2020-11-19 Flodesign Sonics, Inc. Effet de bord acoustique
US20210341370A1 (en) * 2018-10-18 2021-11-04 Smart Material Printing B.V. Particle filter with ultrasound device
CN114345427A (zh) * 2020-10-14 2022-04-15 精工爱普生株式会社 流体设备
US11459540B2 (en) 2015-07-28 2022-10-04 Flodesign Sonics, Inc. Expanded bed affinity selection
US11474085B2 (en) 2015-07-28 2022-10-18 Flodesign Sonics, Inc. Expanded bed affinity selection

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060037915A1 (en) * 2002-06-04 2006-02-23 Protasis Corporation Method and device for ultrasonically manipulating particles within a fluid
US20100206818A1 (en) * 2009-02-19 2010-08-19 Chartered Semiconductor Manufacturing, Ltd. Ultrasonic filtration for cmp slurry
WO2014046605A1 (fr) * 2012-09-21 2014-03-27 Acousort Ab Procédé de séparation de complexes cellules-billes
US20140154795A1 (en) * 2012-03-15 2014-06-05 Flodesign Sonics, Inc. Bioreactor using acoustic standing waves

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060037915A1 (en) * 2002-06-04 2006-02-23 Protasis Corporation Method and device for ultrasonically manipulating particles within a fluid
US20100206818A1 (en) * 2009-02-19 2010-08-19 Chartered Semiconductor Manufacturing, Ltd. Ultrasonic filtration for cmp slurry
US20140154795A1 (en) * 2012-03-15 2014-06-05 Flodesign Sonics, Inc. Bioreactor using acoustic standing waves
WO2014046605A1 (fr) * 2012-09-21 2014-03-27 Acousort Ab Procédé de séparation de complexes cellules-billes

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"Acoustic radiation force of a sphere without restriction to axisymmetric fields", PROCEEDINGS OF MEETINGS ON ACOUSTICS, vol. 19, 2013, pages 045004
YURII ILINSKII; EVGENIA ZABOLOTSKAYA, AIP CONFERENCE PROCEEDINGS, vol. 1474-1, 2012, pages 255 - 258

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11459540B2 (en) 2015-07-28 2022-10-04 Flodesign Sonics, Inc. Expanded bed affinity selection
US11474085B2 (en) 2015-07-28 2022-10-18 Flodesign Sonics, Inc. Expanded bed affinity selection
EP3642621A1 (fr) * 2017-04-26 2020-04-29 Bart Lipkens Sélection de cellule par affinité en lit expansé
US20210341370A1 (en) * 2018-10-18 2021-11-04 Smart Material Printing B.V. Particle filter with ultrasound device
US12303807B2 (en) * 2018-10-18 2025-05-20 Smart Material Printing B.V. Particle filter with ultrasound device
WO2020232370A1 (fr) * 2019-05-15 2020-11-19 Flodesign Sonics, Inc. Effet de bord acoustique
CN113840640A (zh) * 2019-05-15 2021-12-24 弗洛设计声能学公司 声边缘效应
CN114345427A (zh) * 2020-10-14 2022-04-15 精工爱普生株式会社 流体设备

Also Published As

Publication number Publication date
GB201812196D0 (en) 2018-09-12
GB2562937A (en) 2018-11-28
CA3013052A1 (fr) 2017-08-03
GB2562937B (en) 2022-01-05

Similar Documents

Publication Publication Date Title
US10947493B2 (en) Acoustic perfusion devices
US10662402B2 (en) Acoustic perfusion devices
US9738866B2 (en) Acoustic perfusion devices
US9822333B2 (en) Acoustic perfusion devices
CA2900277C (fr) Bioreacteur utilisant des ondes acoustiques stationnaires
US9752114B2 (en) Bioreactor using acoustic standing waves
US9738867B2 (en) Bioreactor using acoustic standing waves
US9783775B2 (en) Bioreactor using acoustic standing waves
US9416344B2 (en) Bioreactor using acoustic standing waves
US20170191022A1 (en) Bioreactor using acoustic standing waves
EP3234099B1 (fr) Dispositifs acoustiques de perfusion
EP3360955A1 (fr) Bioréacteur utilisant des ondes stationnaires acoustiques
CA3034208A1 (fr) Bioreacteur utilisant des ondes stationnaires acoustiques
WO2017132694A1 (fr) Dispositifs de perfusion acoustique
EP3426372A1 (fr) Dispositif d'acoustophorèse à plusieurs étages
EP3341463B1 (fr) Dispositifs de perfusion acoustiques
WO2018187789A1 (fr) Dispositifs de perfusion acoustique

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17708901

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 201812196

Country of ref document: GB

Kind code of ref document: A

Free format text: PCT FILING DATE = 20170130

WWE Wipo information: entry into national phase

Ref document number: 1812196.2

Country of ref document: GB

WWE Wipo information: entry into national phase

Ref document number: 3013052

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17708901

Country of ref document: EP

Kind code of ref document: A1